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Zusammenfassung 
I 
ZUSAMMENFASSUNG 
Solide Tumoren sind oft schlecht durchblutet. Dadurch haben sie eine verringerte Zufuhr an 
Sauerstoff und Nährstoffen, wodurch ihr Wachstum limitiert wird. Sauerstoffmangel führt zu 
Änderungen in der Genexpression – hauptsächlich des Hypoxie-induzierbaren Faktors (HIF) – 
welche es den Krebszellen erlauben, sich an einen tiefen Sauerstoffgehalt anzupassen. Eines dieser 
Zielgene ist Carboanhydrase IX (CA IX), ein Transmembranprotein mit extrazellulärer Domäne, 
welche die reversible Hydratisierung von Kohlenstoffdioxid zu Hydrogencarbonat und Protonen 
katalysiert. CA IX wird hauptsächlich im Tumorgewebe exprimiert und nur sehr selten in 
gesundem Gewebe, wie z.B. dem gastrointestinalen Trakt. Die katalytische Aktivität erleichtert das 
Wachstum von Tumoren durch Senkung des extrazellulären pHs und Neutralisierung des 
intrazellulären pHs. Dadurch ist CA IX einerseits ein vielversprechender Marker für 
Tumortargeting und andererseits ein mögliches Ziel für eine die CA IX Aktivität inhibierende 
Tumortherapie. In der Klinik werden mehrere synthetische Stoffe eingesetzt, welche die CA IX 
Aktivität inhibieren. Da diese aber auch mit anderen Carboanhydrase Isoformen interagieren, 
haben sie häufig schwere Nebenwirkungen, und ihr Einsatz in der Klinik ist limitiert. Daneben 
verwendet man Antikörper, die CA IX sehr spezifisch binden. Diese sind sehr hilfreich im 
Visualisieren von Tumoren, leider ist ihre therapeutische Wirkung jedoch umstritten. Das Ziel 
dieser Doktorarbeit war es daher, CA IX spezifische Antikörper mit Enzym-inhibitorischer Aktion 
zu etablieren, um effizientere Therapien gegen solide Tumoren zu entwickeln. 
In dieser Arbeit wurden mit Hilfe des Phagendisplays zwölf Fab-Antikörper (MSC 1 – 12) 
selektioniert, die spezifisch an rekombinantes humanes CA IX binden. Keine unspezifische 
Bindung an andere Isoformen mit sehr grosser Homologie, namentlich CA II, CA XII oder 
CA XIV, wurde beobachtet, was die selektive Bindung an CA IX bestätigt. Zusätzlich waren zwei 
Antikörper, MSC 1 und MSC 3, kreuzreaktiv mit murinem CA IX. MSC 3 IgG färbte murines 
CA IX spezifisch in Tumorschnitten und kann daher in einem syngenen Mausmodell eingesetzt 
werden.  
Fünf Antikörper, MSC 2, MSC 5, MSC 8, MSC 10 und MSC 12, waren in der Lage, die 
enzymatische Funktion von CA IX in einem biochemischen Assay auf Membranfragmenten 
teilweise zu inhibieren. Der vielversprechendste der Antikörper, MSC 8, inhibierte die CA IX 
Aktivität um 57 % als Fab-Antikörper und um 76 % als bivalenter IgG. Zudem inhibierte MSC 8 
Fab die CA IX Aktivität auf intakten Einzelzellen um 48 % bzw. MSC 8 IgG um 61 %. Daneben 
bewirkte MSC 8 IgG die Internalisierung von CA IX, wodurch die CA IX Aktivität auf der 
Zelloberfläche weiter reduziert werden dürfte. 
Daher könnte der humane CA IX spezifische IgG MSC 8 einen weitaus grösseren Nutzen haben als 
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zuvor entwickelte anti-CA IX Antikörper, indem Spezifität mit Inhibition der CA IX Enzym-
Aktivität gekoppelt wird. Der therapeutische Effekt könnte weiter gesteigert werden, indem 
biologisch aktive Substanzen mit Hilfe dieser Antikörper spezifisch zu Zielzellen gebracht werden 
und durch Internalisierung direkt an ihren Wirkungsort gelangen. 
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ABSTRACT 
The growth of solid tumours is limited by low supply of oxygen and nutrients due to poor 
vascularisation. Hypoxia leads to changes in gene expression mostly due to the hypoxia inducible 
factor (HIF), helping cancer cells to adapt to low oxygen levels. One of these target genes is 
carbonic anhydrase IX (CA IX), a transmembrane protein with an extracellular domain catalysing 
the reversible hydration of carbon dioxide to hydrogen carbonate and protons. CA IX expression is 
mostly limited to hypoxic tumour tissues. It is only rarely expressed in normal tissue, e.g. in the 
gastrointestinal tract. Its catalytic activity facilitates tumour growth by acidification of extracellular 
pH and neutralisation of intracellular pH. This makes carbonic anhydrase IX not only a promising 
marker for tumour targeting but also a potential target for tumour therapy by inhibiting CA IX 
enzymatic activity. Several chemical compounds inhibiting CA IX activity are used in the clinic. 
However, due to cross-reactivity with other carbonic anhydrase isoforms, they have severe side 
effects and their clinical use is very much limited. On the other hand, antibodies specifically 
targeting CA IX have proven to be very useful in tumour imaging, but their therapeutic effect is 
disputed. The aim of this thesis was therefore to establish CA IX specific antibodies blocking 
enzymatic activity in order to enhance efficacy of therapies against solid tumours. 
In this thesis, twelve Fab antibodies, called MSC 1 – 12, specifically recognizing human CA IX 
were selected by phage display on recombinant human CA IX. No unspecific binding to any of the 
other highly homologous isoforms CA II, CA XII or CA XIV could be detected, confirming highly 
selective binding to CA IX. In addition, two of the antibodies, MSC 1 and MSC 3, were cross-
reactive to murine CA IX. MSC 3 IgG specifically stained murine CA IX in tumour sections and 
can thus be used in syngeneic mouse models. 
Five antibodies, MSC 2, MSC 5, MSC 8, MSC 10 and MSC 12, inhibited CA IX function partially 
in a biochemical assay on membrane fragments. The most potent of those antibodies, MSC 8, 
inhibited CA IX activity by up to 57 % as Fab antibody and 76 % as bivalent IgG. In addition, 
MSC 8 inhibited CA IX activity on intact single cells by 48 % and 61 % for MSC 8 Fab and 
MSC 8 IgG, respectively. In addition, MSC 8 IgG triggered CA IX internalisation which might 
further reduce CA IX activity on the cell surface. 
Therefore, the fully human CA IX-specific IgG antibody MSC 8 may extend beyond the use of 
previously developed CA IX-antibodies by combining target-specificity with CA IX inhibitory 
activity. By delivering therapeutic moieties specifically to target cells and triggering internalisation 
of those compounds the here selected antibodies could further increase therapeutic efficacy. 
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 1.1 Hypoxia 
1 
1 INTRODUCTION 
The immune system is able to discriminate between self and non-self allowing immune cells to 
specifically target foreign structures and protect the body from invasion of pathogens. 
Nevertheless, there are diseases, where our immune system is impaired in its ability to protect the 
body. The most important of those diseases is cancer, the second most common cause of death in 
Europe and the US. Tumour cells are derived from normal tissue cells making it hard for the 
immune system to selectively target them. However, several proteins are upregulated and 
predominantly expressed in cancer cells. These antigens are called tumour associated antigens 
(TAA). In tumour therapy, TAA display important targets for selective treatment of tumours where 
surgery is not possible. Carbonic anhydrase IX targeted in this study is a TAA found in a variety of 
solid tumours due to its tight regulation by hypoxia, a hallmark of solid tumours. 
 
1.1 HYPOXIA 
Höckel and Vaupel define hypoxia as a “state of reduced oxygen (O2) availability or decreased O2 
partial pressure (pO2) below critical thresholds, thus restricting or even abolishing the function of 
organs, tissues or cells”. Tissue hypoxia results from inadequate supply of oxygen and can be 
caused by reduced pO2 of the blood (hypoxemic hypoxia), reduced ability of the blood to transport 
O2 (anaemic hypoxia), reduced tissue perfusion (circulatory or ischemic hypoxia), deterioration of 
the diffusion geometry (diffusional hypoxia) or impaired ability of cells to use O2 (histotoxic or 
cytotoxic hypoxia). Reduced oxygen levels impede oxidative phosphorylation in hypoxic areas 
leading to enhanced anaerobic respiration, followed by lactic acid fermentation and reduced ATP 
production (reviewed in (Hockel and Vaupel 2001)).  
 
1.1.1 Hypoxia and cancer 
In solid tumours, uncontrolled cell division leads to inadequate supply of tumour tissue with 
nutrients and oxygen due to increasing distance to blood vessels. With increasing distances from 
blood vessels, pO2 decreases (Figure  1.1 A) (Helmlinger, Yuan et al. 1997). Growth of solid tumours 
is therefore limited by vascularisation (reviewed in (Carmeliet and Jain 2000)). In addition, tumour 
blood vessels are often highly disorganized leading to diffusional hypoxia and the transport 
capacity of the blood for O2 is often reduced due to anaemia (reviewed in (Hockel and Vaupel 
2001)). Even regions adjacent to blood vessels can show a hypoxic phenotype and very low 
extracellular pH (pHe) (Helmlinger, Yuan et al. 1997), possibly due to elevated production of lactic 
acid. Additionally, also under normoxic conditions many tumours have a high rate of anaerobic 
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glycolysis followed by lactic acid fermentation. They often show a mixed metabolism with 
oxidative phosphorylation and anaerobic respiration at the same time, although exact mechanisms 
are not yet known (reviewed in (Stubbs, McSheehy et al. 2000)). In the 1930s, Warburg 
demonstrated that cancer cells have an elevated rate of lactate production, leading to the 
assumption that tumour cells would have an acidic intracellular pH (pHi). However some 50 years 
later it became evident that pHi was indeed neutral or even slightly alkaline, because lactate is not 
deposited intracellularly but exported - mainly through the H+-monocarboxylate co-transporter. 
Accumulation of this metabolite and slow clearance due to poor vascularisation lead to 
acidification of the tumour stroma (reviewed in (Stubbs, McSheehy et al. 2000)). This decrease in 
pHe following a decrease in pO2 (Figure  1.1 B) (Helmlinger, Yuan et al. 1997) is not only caused by 
elevated production of lactic acid and slow clearance of the same, but also by other means, e.g. 
carbon dioxide (Dubois, Douma et al. 2007). In contrast to normal tissue, tumour cells show 
therefore a reversed pH gradient across the cell membrane with a rather high pHi and a low pHe 
(reviewed in (Stubbs, McSheehy et al. 2000)). The local glucose and oxygen availability both 
affect tumour acidity independently (Helmlinger, Sckell et al. 2002).  
Tumour hypoxia augments the malignant potential of neoplasms – possibly due to genomic 
instability coupled to impaired repair mechanisms and to upregulation of transcription factors such 
as hypoxia inducible factor 1 (HIF-1) (reviewed in (Huang, Bindra et al. 2007)). Low pHe might be 
an intrinsic feature of cancer phenotype facilitating tumour progression, tumourigenic 
transformation, chromosomal rearrangement, extracellular matrix break-down, migration and 
invasion, as well as induction of expression of cell growth factors and proteases (reviewed in 
(Stubbs, McSheehy et al. 2000)). 
 
 
 
  
Figure  1.1: pO2 and pH gradients with increasing distance from blood vessels. (A) Schematic representation of 
hypoxic tissue. Blood vessels supply cells with oxygen and nutrients. With increasing distance to blood vessels pO2 
therefore decreases. From (Carmeliet and Jain 2000). (B) Measurement of pO2 and pH in the tissue. Both, pO2 (filled 
triangles) and pH (open boxes) decrease with increasing distance from blood vessels. From (Helmlinger, Yuan et al. 
1997). 
(A) (B) 
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It is not possible to state one single general threshold for hypoxia and the hypoxic state can not be 
predicted by size, stage or grade of a tumour. Usually, the oxygen state (median pO2) of tumour 
tissues is reduced compared to the tissue of origin with recurring tumours having an even lower 
oxygen state than corresponding primary tumours (reviewed in (Hockel and Vaupel 2001)). A 
number of invasive as well as non-invasive techniques to analyze the oxygenation state of tumours 
are available (reviewed in (Hockel and Vaupel 2001)). Methods to quantify tumour hypoxia are 
very important in order to find optimal tumour therapies, since hypoxia as well as pH has an impact 
on therapy outcome. Radiotherapy depends on oxygen availability to generate free oxygen radicals 
damaging the DNA (Figure  1.2). Additionally, hypoxia-induced upregulation of heat-shock proteins 
might further protect tumour cells from effects of radiotherapy and therefore reduces therapeutic 
efficacy. Similarly, several anticancer agents depend on the availability of oxygen. Finally, hypoxia 
alters the potency of cytokines (reviewed in (Hockel and Vaupel 2001)). Low pHe leads to 
chemoresistance possibly due to decreased uptake of weakly basic cancer drugs (Raghunand, He et 
al. 1999). Drug transport is mediated by active transport or passive diffusion, with weak 
electrolytes entering the cell by passive diffusion of the non-ionized form. Depending on the drug, 
a lower or higher pHe favours building of the non-ionized form and thus drug-uptake (Figure  1.3). 
The ionized form is then thought to get stuck in the cytoplasm. Since uptake is pH-dependent, pHi 
as well as pHe could have an impact on chemoresistance (reviewed in (Stubbs, McSheehy et al. 
2000)). Additionally, drug toxicity can depend on pH (reviewed in (Stubbs, McSheehy et al. 
2000)). All this factors are possible causes why hypoxic tumours often lead to poor prognosis. 
Inhibition of factors regulating tumour pH might therefore augment effects of chemotherapy and 
reduce tumour progression by reducing metastases (Raghunand, He et al. 1999). 
 
 
Figure  1.2: influence of hypoxia on malignant progression of tumours. Uncontrolled cell division leads to hypoxic 
conditions due to increased cell number and poor supply of oxygen. Hypoxia augments genomic instability and selection 
pressure leading to clonal selection of variants promoting tumour growth. Altered cells and hypoxia impede tumour 
therapy. From (Hockel and Vaupel 2001) 
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Figure  1.3: Modulation of tumour pH to increase uptake of chemotherapeutic drugs. The figure indicates the 
modulation (decrease or increase) of pH necessary to increase the uptake of the named drugs used in chemotherapy. The 
drugs are weak electrolytes. 5-Fluorouracil: uracil analogue; camptothecin: inhibitor of topoisomerase I; adriamycin 
(= doxorubicin) and mitoxantrone: DNA intercalating agents; vinblastine: mitose inhibitor. From (Stubbs, McSheehy et 
al. 2000) 
 
1.1.2 Hypoxia inducible factor 1 (HIF-1) 
The hypoxia inducible factor 1 (HIF-1) is a transcription factor regulating gene expression under 
hypoxic conditions. It is a heterodimer consisting of the two subunits HIF-1 and HIF-1 (Wang 
and Semenza 1995). The -subunit is present in the cytosol and the -subunit shown to be identical 
to the aryl hydrocarbon receptor nuclear translocator (ARNT) (Wang, Jiang et al. 1995) is 
constitutively expressed in the nucleus. HIF-1 is regulated by stabilization of its -subunit (Figure 
 1.4) (Huang, Arany et al. 1996). Although constitutively expressed, under normoxic conditions 
HIF-1 is quickly degraded (Huang, Arany et al. 1996). Hydroxylation of its oxygen-dependent 
degradation (ODD) domain (Huang, Gu et al. 1998) by oxygen-dependent prolyl-4-hydroxylase 
domain proteins (PHDs) (Jaakkola, Mole et al. 2001) and subsequent binding of the von Hippel-
Lindau tumour-suppressor protein (pVHL) (Maxwell, Wiesener et al. 1999; Jaakkola, Mole et al. 
2001) results in ubiquitination by pVHL (Ohh, Park et al. 2000) and proteasomal degradation 
(Huang, Gu et al. 1998). Under hypoxic conditions on the other hand, hydroxylation of HIF-1 can 
not take place and pVHL can not bind (Jaakkola, Mole et al. 2001). The -subunit is stabilized and 
can translocate into the nucleus where it binds the -subunit, building the active transcription factor 
HIF-1 which binds to hypoxia responsive elements (HRE) of target genes (Figure  1.5) (reviewed in 
(Thiry, Dogne et al. 2006)). Target genes include among others glucose transporter GLUT-1 
(Ebert, Firth et al. 1995) involved in glucose metabolism, vascular endothelial growth factor 
(Forsythe, Jiang et al. 1996) triggering neoangiogenesis (Shweiki, Itin et al. 1992) and carbonic 
anhydrase IX (Wykoff, Beasley et al. 2000), a protein involved in pH-regulation.  
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Figure  1.4: Induction of HIF-1 by hypoxia. Under normoxic conditions, ubiquitination by pVHL leads to proteosomal 
degradation of HIF-1. Under hypoxic conditions pVHL can not bind and HIF-1 translocates to the nucleus where it 
binds HIF-1 building the active transcription factor HIF-1 which induces transcription of target genes. From (Thiry, 
Dogne et al. 2006) 
 
 
Figure  1.5: HIF target genes. Protein products of the genes are shown for which there is evidence of direct 
transcriptional activation by the hypoxia-inducible factor. Those proteins are involved in many functions important under 
conditions of low oxygen and in solid tumours, e.g. energy metabolism and angiogenetic signalling. From (Schofield and 
Ratcliffe 2004). 
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Figure  1.6: Mechanism of -CA catalytic activity. (A) In the active form of the enzyme a hydroxide is bound to Zn2+. 
(B) This strong nucleophile attacks a CO2 molecule bound in a hydrophobic pocket in its neighbourhood, (C) leading to 
the formation of hydrogen carbonate coordinated to Zn2+. (D) The hydrogen carbonate ion is then displaced by a water 
molecule. The enzyme contains now a water molecule coordinated to Zn2+. A proton transfer reaction restores the 
original active form. This reaction can be assisted either by active site residues (e.g. His 64—the proton shuttle in CA II 
and CA IX) or by buffers. Numbers are given for CA II. From (Supuran 2004). 
 
 
1.2 CARBONIC ANHYDRASES 
One of the genes regulated by HIF-1 is carbonic anhydrase IX (CA IX). Like all animal kingdom 
carbonic anhydrases (CAs) characterized so far, CA IX belongs to the -CAs (Hewett-Emmett and 
Tashian 1996). Carbonic anhydrases are metalloenzymes containing a Zn2+-ion essential for 
catalytic activity (Figure  1.6). Enzymatic active carbonic anhydrases trigger the reversible hydration 
of carbon dioxide to hydrogen carbonate and protons (Sly and Hu 1995): 
H2O + CO2   HCO3- + H+ 
Due to the conversion of carbon dioxide to hydrogen carbonate, carbonic anhydrases directly 
influence the hydrogen carbonate buffering system - an important buffering system in humans. 
Carbonic anhydrases therefore have a huge impact on physiological processes like acid-base 
regulation, respiration, electrolyte secretion, bone resorption and biosynthetic reactions using 
hydrogen carbonate as a substrate (reviewed in (Pastorekova, Parkkila et al. 2004; Supuran 2004)). 
 1.2 Carbonic anhydrases 
7 
Table  1.1: Localization and activity of higher vertebrate carbonic anhydrases. Different isozymes differ in their 
subcellular localization and in their catalytic rate. Adapted from (Supuran 2004; Nishimori, Vullo et al. 2005) 
Isozyme catalytic activity subcellular location 
CA I low cytosol 
CA II high cytosol 
CA III very low cytosol 
CA IV high membrane bound 
CA VA low mitochondria 
CA VB high mitochondria 
CA VI moderate secreted into saliva 
CA VII high  cytosol 
CARP VIII acatalytic cytosol 
CA IX high transmembrane 
CARP X acatalytic cytosol 
CARP XI acatalytic cytosol 
CA XII low transmembrane 
CA XIII moderate cytosol 
CA XIV low transmembrane 
 
Of the 16 mammalian -CA isoforms 13 are enzymatically active (CA I (Barlow, Lowe et al. 
1987), CA II (Montgomery, Venta et al. 1987), CA III, CA IV (Zhu and Sly 1990), CA VA 
(Nagao, Platero et al. 1993), CA VB (Fujikawa-Adachi, Nishimori et al. 1999), CA VI, CA VII, 
CA IX, CA XII (Ivanov, Kuzmin et al. 1998; Tureci, Sahin et al. 1998), CA XIII (Lehtonen, Shen 
et al. 2004), CA XIV and CA XV which is not expressed in humans (Hilvo, Tolvanen et al. 2005)) 
and three appear to lack any catalytic activity and are therefore called carbonic anhydrase related 
proteins (CARP VIII, CARP X and CARP XI) (reviewed in (Supuran 2004)). 
Carbonic anhydrase isoforms differ in their rate of catalytic activity and their subcellular 
localization (Table  1.1) (reviewed in (Supuran 2004)), with membrane associated carbonic 
anhydrases having an extracellular active site influencing various extracellular physiological 
processes like extracellular pH-regulation, as well as in their expression profiles (Pan, Leppilampi 
et al. 2006). In a particular mammalian tissue or organ, often multiple isozymes are co-expressed 
suggesting distinct functions for different isozymes, which might sometimes be redundant. Loss of 
one isozyme might therefore be compensated by another one (Pan, Leppilampi et al. 2006). In the 
stomach of CA II deficient mice, CA IX levels are indeed upregulated. Interestingly, in brain, colon 
or kidney this upregulation is not observed (Pan, Leppilampi et al. 2006). 
CA II is the most widely expressed isozyme, present in all major mammalian organs (Pan, 
Leppilampi et al. 2006). Broad expression and high activity propose CA II to play a role in several 
fundamental biological processes (Parkkila, Parkkila et al. 1994; Sly and Hu 1995). 
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Figure  1.7: Expression of tumour-associated carbonic anhydrases. (A) CA IX and CA XII are both abundant in 
tumour tissue. (B) CA XII is broadly expressed in normal tissue, whereas CA IX expression is restricted to the 
gastrointestinal tract. Dark grey: high expression, light grey: low expression, white: no expression. From (Pastorekova 
and Pastorek 2004). 
 
Two membrane-associated catalytically active isozymes, CA IX and CA XII, are abundant in many 
tumours (Pastorekova, Zavadova et al. 1992; Pastorek, Pastorekova et al. 1994; Tureci, Sahin et al. 
1998; Wykoff, Beasley et al. 2000) due to their induction by hypoxia (Figure  1.7 A) (Ivanov, 
Kuzmin et al. 1998). In pVHL deficient cells, CA IX and CA XII both are expressed constitutively 
(Ivanov, Kuzmin et al. 1998; Wykoff, Beasley et al. 2000), but an influence of pVHL on the 
expression of other CA isoforms is not known so far. CA IX was the first carbonic anhydrase 
shown to be predominantly expressed in cancer tissue (reviewed in (Pastorekova and Pastorek 
2004)) and its role is much better understood than the one of CA XII. CA IX is generally accepted 
as a sensitive and rather specific marker for conventional renal cell carcinomas (RCC) (Li, 
Cuilleron et al. 2003) and was suggested to serve as marker for hypoxia (Wykoff, Beasley et al. 
2000). 
CA IX and CA XII promote cell survival and growth through maintenance of pHi (as described in 
detail in  1.3.3 CA IX function) in cells exposed to hypoxic and acidic microenvironment. Their 
expression protects cells against cytoplasmic acidification and sustains ATP levels (Chiche, Ilc et 
al. 2009). Tumour growth in xenograft mice was significantly decreased after silencing of either 
hif-1 or its target genes ca9 and ca12. Silencing of both target genes led to an 85% reduction of 
tumour growth as a result of reduced cell proliferation. In contrast, silencing of ca9 only gave a 
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40% reduction and ca12 alone did not lead to any significant decrease in tumour growth. CA IX 
and CA XII therefore work synergistically (Chiche, Ilc et al. 2009). Furthermore, in vivo silencing 
of ca9 can be partially compensated by increased CA XII expression while the reverse case has not 
been reported (Chiche, Ilc et al. 2009).  
Although CA IX and CA XII both are associated with solid tumours, they are also expressed in a 
number of normal tissues (Figure  1.7 B). For CA IX, expression in normal tissue is restricted to the 
gastrointestinal tract, but CA XII is found in a broad range of normal tissue (Ivanov, Kuzmin et al. 
1998; Tureci, Sahin et al. 1998; Pastorekova and Pastorek 2004). 
 
1.3 CARBONIC ANHYDRASE IX (CA IX) 
CA IX was the first carbonic anhydrase found to be associated with cancer. It was originally 
described in dense cultures (Pastorekova, Zavadova et al. 1992) and only later prevalence under 
hypoxic conditions became evident (Wykoff, Beasley et al. 2000). 
 
1.3.1 CA IX structure 
The full length cDNA of CA IX was first cloned by Pastorek et al. in 1994 (Pastorek, Pastorekova 
et al. 1994). Two years later, the CA IX gene was sequenced and characterized by Opavsky et al. 
(Opavsky, Pastorekova et al. 1996).  
The CA IX protein sequence consists of 459 amino acids (aa) and has a calculated molecular 
weight of 49.7 kDa (Opavsky, Pastorekova et al. 1996). CA IX consists of 4 different domains: a 
short N-terminal signal peptide (SP, aa 1-37), a proteoglycan-like domain (PG domain, aa 53-111) 
unique to CA IX and involved in cell adhesion processes (Zavada, Zavadova et al. 2000), an 
extracellular carbonic anhydrase domain (CA domain, aa 135-391) with catalytic activity, a single 
hydrophobic transmembrane domain (TM domain, aa 415-436) and an intracellular C-terminal 
domain (IC domain, aa 436-459) necessary for proper function of CA IX (Hulikova, Zatovicova et 
al. 2009) (Figure  1.8) (Pastorek, Pastorekova et al. 1994; Opavsky, Pastorekova et al. 1996; 
Pastorekova and Pastorek 2004; Morgan, Pastorekova et al. 2007).  
 
 
Figure  1.8: Domain organization of CA IX. CA IX consists of a short signal peptide (SP), a proteoglycan-like (PG) 
domain, the extracellular carbonic anhydrase (CA) domain with catalytic activity, a single transmembrane (TM) domain 
and an intracellular (IC) domain. From (Thiry, Dogne et al. 2006) 
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Table  1.2: Homology of the CA domain of CA IX compared to the CA domain of different isozymes. The CA IX 
catalytic domain is highly homologous to the CA domains of other isozymes. Data from (Opavsky, Pastorekova et al. 
1996) 
 
 
The CA domain of CA IX is highly homologous to the CA domains of other carbonic anhydrases 
(Table  1.2) (Opavsky, Pastorekova et al. 1996), with the zinc-binding histidyl residues as well as the 
other residues in the active site being conserved (Pastorek, Pastorekova et al. 1994). Also the C-
terminal part shows high homology to other carbonic anhydrases in contrast to the N-terminal part 
(Pastorek, Pastorekova et al. 1994). Indeed, CA IX is the only carbonic anhydrase isoform known 
so far to posses a PG domain, showing 38 % homology to the keratin sulphate attachment domain 
of the proteoglycan aggrecan (Doege, Sasaki et al. 1991; Opavsky, Pastorekova et al. 1996). 
In SDS-PAGE analysis, CA IX migrates as a double band of 54 kDa and 58 kDa (Pastorekova, 
Zavadova et al. 1992; Pastorek, Pastorekova et al. 1994), the origin of which is unknown. Both 
polypeptides originate from the same mRNA (Pastorek, Pastorekova et al. 1994). Although CA IX 
contains a N-glycosylation site (Asn346) within the CA domain (Hilvo, Baranauskiene et al. 2008) 
(for sequence and numbering see  5.1.2 CA IX amino acid sequence), the double band does not origin 
from different glycosylation patterns (Pastorek, Pastorekova et al. 1994; Hilvo, Baranauskiene et al. 
2008).  
 
Figure  1.9: Stereoview of the active site region of CA IX bound by acetazolamide. Acetazolamide inhibits CA IX 
function by binding to the Zn2+-ion in the active site necessary for catalytic activity. From (Alterio, Hilvo et al. 2009). 
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Figure  1.10: X-ray structure of the dimeric catalytic domain. (A) The X-ray structure of the catalytic domain of 
CA IX shows formation of a CA IX dimer. (B) The proposed structure of the full length CA IX dimer is based on the X-
ray structure of the dimeric catalytic domain (blue). The hypothetical arrangement of the PG domains (magenta), the 
transmembrane helices (yellow), the cytoplasmic domains (green) and the glycan moieties (white) attached to the 
catalytic domain (blue) is schematically reported. From (Alterio, Hilvo et al. 2009). 
 
Recombinant protein obtained by a mammalian expression system in addition demonstrated the 
occurrence of an O-linked glycosylation site (Thr115) containing oligosaccharides highly similar to 
those in the proteoglycan domain of other proteins involved in cell adhesion processes and tumour 
progression (Hilvo, Baranauskiene et al. 2008). CA IX contains three putative phosphorylation 
sites at the cytoplasmic tail, possibly leading to intracellular signalling (reviewed in (Thiry, Dogne 
et al. 2006)). CA IX is very stable (Pastorek, Pastorekova et al. 1994) with a half life of 
approximately 38 h (Rafajova, Zatovicova et al. 2004).  
In 2009, Alterio et al managed to co-crystallize the catalytic domain of CA IX with acetazolamide, 
a broad range carbonic anhydrase inhibitor (Figure  1.9), showing that CA IX forms dimers linked by 
disulfide bonds (Figure  1.10) (Alterio, Hilvo et al. 2009). There is one intramolecular disulfide bond 
(Cys156 - Cys336), as well as two cysteins (Cys174 and Cys409) able to form intermolecular disulfide 
bonds (Hilvo, Baranauskiene et al. 2008). Since up to date there does not exist any full length 
crystal structure of CA IX, it can not be excluded, that the transmembrane domain or the 
intracellular tail is necessary for correct multimerization and that the full length protein might form 
other multimers. Previous studies based on SDS-PAGE under non-reducing conditions showed 
several bands around 150 kDa suggesting a trimeric form (Pastorekova, Zavadova et al. 1992; 
Svastova, Hulikova et al. 2004).  
Recent studies indicate that under hypoxia there exists a special hypoxic conformation of CA IX 
which is the catalytically active conformation. CA IX activity thus depends not only on protein 
upregulation via HIF-1 but also on the formation of the active conformation by the absence of 
(A) (B) 
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oxygen per se (Dubois, Douma et al. 2007). Studies using a chemical compound specifically 
recognizing the active conformation of CA IX suggest that formation of the active conformation 
does not require de novo protein synthesis but displays a fast oxygen mediated effect. The active 
conformation is reached within 15 min of hypoxic exposure and is gradually lost after re-
oxygenation with a half-life time of approximately 30 min (Dubois, Douma et al. 2007). 
 
 
1.3.2 CA IX expression 
The gene coding for CA IX is conserved in a single copy in the human genome on chromosome 
9p12-13 (Grabmaier, Vissers et al. 2000) as well as in different vertebrate species (Pastorek, 
Pastorekova et al. 1994; Opavsky, Pastorekova et al. 1996). CA IX is often expressed in tumour 
tissues but only rarely in normal tissues (Figure  1.11) (Pastorek, Pastorekova et al. 1994; Wykoff, 
Beasley et al. 2000). The most abundant expression of CA IX in normal tissue is found within the 
epithelial cells of normal gastric mucosa (Pastorek, Pastorekova et al. 1994). It is located at the 
basolateral surface possibly involved in maintaining gastric mucosa integrity and balance between 
cell differentiation and proliferation. 
 
 
 
 
Figure  1.11: Expression of CA IX in normal and tumour tissue. In normal tissue CA IX expression is restricted to the 
gastrointestinal tract, whereas it is highly abundant in tumour tissue. Dark grey: high expression, light grey: low 
expression, white: no expression. Adapted from (Pastorekova and Pastorek 2004). 
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Upregulation of CA IX in cancer tissue is not due to mutations in the gene (Grabmaier, Vissers et 
al. 2000) but to hypoxic conditions. CA IX contains a HRE-Element and is thus upregulated by 
hypoxia through HIF-1 as shown in  1.1.2 Hypoxia inducible factor 1 (HIF-1). Since HIF-1 is 
downregulated by pVHL, pVHL deficient tumours e.g. RCC containing a mutation in the gene 
encoding pVHL (Gnarra, Tory et al. 1994) express CA IX constitutively and with uniform 
distribution (Wykoff, Beasley et al. 2000). In contrast CA IX is heterogeneously und mostly 
perinecrotic distributed in non-pVHL deficient tumours where expression is regulated by HIF-1 
and hypoxia (Wykoff, Beasley et al. 2000). Interestingly, in tissues expressing CA IX this 
expression is decreased or even lost during carcinogenesis (reviewed in (Pastorekova and Pastorek 
2004)). 
Beside its upregulation under low oxygen levels (true hypoxia) by HIF-1, a second pathway of 
CA IX regulation is suggested, occurring at intermediate oxygen levels as found in dense cultures 
due to depletion and limited diffusion (Kaluz, Kaluzova et al. 2002). It is supposed that density-
mediated upregulation is independent of HIF-1 stabilization since HIF-1 levels are not changed in 
conditions of dense cultures. Nevertheless a minimal level of HIF-1 activity is required, as shown 
by the necessity of HRE for density-mediated CA IX expression (Kaluz, Kaluzova et al. 2002). 
Density-mediated upregulation is independent of anchorage, growth factors contained in serum, pH 
or glucose concentration. The only known factor in cell-density mediated upregulation is 
phosphatidylinositol 3-kinase (PI3K), although the exact mechanism is not yet known (Kaluz, 
Kaluzova et al. 2002). Tumours with deregulated PI3K activity might therefore express CA IX 
constitutively. Effects of hypoxia and density-mediated CA IX expression are additive suggesting 
that they are due to independent mechanisms (Kaluz, Kaluzova et al. 2002). 
Since CA IX expression is influenced by HIF-1, PHD-inhibitors like dimethyloxaloylglycine 
(DMOG) (Asikainen, Ahmad et al. 2005) or iron-chelators, e.g. desferrioxamine (DFO) (Wang and 
Semenza 1993) complexing the iron in the catalytic centre of PHDs, lead to upregulation of CA IX 
in vitro by indirect stabilization of HIF-1. Activation by metal ions like cobalt chloride is 
achieved by a yet unknown mechanism that might depend on PHDs (Yuan, Hilliard et al. 2003; 
Schofield and Ratcliffe 2004), on inhibiting binding of pVHL to hydroxylated HIF-1 (Yuan, 
Hilliard et al. 2003) or on reactive oxygen species and PI3K activity (Triantafyllou, Liakos et al. 
2006 ). 
There have been differing reports on influence of the PI3K/Akt pathway on HIF activity and 
corresponding downstream CA IX gene regulation (Arsham, Plas et al. 2002; Pore, Jiang et al. 
2006; Shafee, Kaluz et al. 2009). Correlations might be cell type specific, although a certain level 
of PI3K/Akt activity was proposed to be necessary for HIF-1 down-stream target activity (Shafee, 
Kaluz et al. 2009).  
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Figure  1.12: A hydrogen carbonate transport metabolon. Schematic model of a transport metabolon consisting of an 
anionic exchanger (AE), CA II and CA IV. The transport metabolon enhances hydrogen carbonate flux across the cell 
membrane. Extracellular CA IV provides hydrogen carbonate which is transported in the cytosol by AE where it is 
consumed by intracellular CA II. The reaction can also take place in the reverse direction facilitating hydrogen carbonate 
efflux. From (Sterling, Alvarez et al. 2002) 
 
1.3.3 CA IX function 
CA IX influences pH (see  1.2 Carbonic anhydrases). It is one of the most active carbonic anhydrase 
isozymes (Hilvo, Baranauskiene et al. 2008) with a catalytic rate constant kcat of 3.8·105 s-1 and 
kcat/Km of 5.5·107 M-1s-1 (reviewed in (Thiry, Dogne et al. 2006)) and an extracellular catalytic 
domain (Opavsky, Pastorekova et al. 1996). Thus, Svastová et al suggested a role of CA IX in the 
control of pHe (Svastova, Hulikova et al. 2004). It seems plausible that low pHe in tumours is 
associated not only with production of lactic acid due to high glycolysis but also with carbon 
dioxide hydration (Helmlinger, Sckell et al. 2002) catalyzed by CA IX (Dubois, Douma et al. 
2007).  
There is evidence that CA IX has also an impact on pHi (Chiche, Ilc et al. 2009), possibly by 
association with anionic exchangers or Na+/HCO3- co-transporters building a so called hydrogen 
carbonate transport metabolon (Morgan, Pastorekova et al. 2007). This transport metabolon 
facilitates the transport of hydrogen carbonate across the membrane (Morgan, Pastorekova et al. 
2007). CA IX leads to production of extracellular hydrogen carbonate, which then might be 
transported into the cytosol by anionic exchangers or Na+/HCO3- co-transporters. In combination 
with intracellular CA II, hydrogen carbonate in the cytosol might be converted to carbon dioxide 
which can diffuse across the plasma membrane. This transport metabolon might therefore sustain a 
hydrogen carbonate influx across the membrane and thus neutralizes the cytosolic acid load 
produced in many tumour cells by anaerobic glycolysis.  
CA II and CA IV have been described earlier to participate in such a hydrogen carbonate transport 
metabolon (Figure  1.12) (Vince and Reithmeier 1998; Sterling, Reithmeier et al. 2001; Sterling, 
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Alvarez et al. 2002; Loiselle, Morgan et al. 2004; Alvarez, Vilas et al. 2005). The first evidence for 
a hydrogen carbonate transport metabolon involving CA IX came from Morgan et al. Direct 
interaction of CA IX with several AE could be shown, with the CA domain of CA IX necessary for 
assembly of the transport metabolon (Morgan, Pastorekova et al. 2007).  
Beside its influence on pH regulation, CA IX has important functions in cell-adhesion processes 
(Zavada, Zavadova et al. 2000; Svastova, Zilka et al. 2003). In polarized Madin Darby canine 
kidney (MDCK) epithelial cells, CA IX co-localizes with E-cadherin at sites of cell-cell adhesion. 
Association of CA IX with -catenin, -catenin and E-cadherin diminishes binding of E-cadherin 
to -catenin, thereby disrupting cell contacts and reducing cell-cell adhesion capacity (Svastova, 
Zilka et al. 2003). For cell-adhesion, full-length protein is required. Zavada et al. showed that the 
binding site of CA IX for cell-receptors lies within the PG-domain and is identical to the epitope of 
the antibody M75 (discussed in detail in  1.4.2 Antibodies against CA IX) (Zavada, Zavadova et al. 
2000). 
In addition to these two generally accepted functions in pH-regulation and cell-adhesion, several 
additional functions for CA IX have been proposed by Wang and coworkers. They suggested 
CA IX to have chaperone-like functions, complexing antigens at 37 °C, to serve as 
immunoadjuvans and to stimulate an adaptive immune response against tumour antigens. They 
therefore proposed CA IX to have an analogous role in activating the immune system as heat shock 
proteins but under hypoxic conditions rather than heat shock. They further showed CA IX to bind 
to dendritic cells in a receptor-specific manner and to be processed primarily through the 
proteosomal pathway leading to cross-presentation (Wang, Wang et al. 2008). 
 
1.4 CA IX AS TARGET IN TUMOUR THERAPY 
CA IX is expressed in many tumours but only rarely in normal tissue. Additionally, CA IX function 
was shown to promote tumour growth and progression by influencing pH and cell adhesion (see 
 1.3.3 CA IX function). Therefore, it is an interesting target for tumour therapy. Such new therapies are 
needed since some solid tumours, e.g. metastatic RCC, are resistant to conventional therapy 
(reviewed in (Motzer, Russo et al. 1997; Lilleby and Fossa 2005)). 
 
1.4.1 Chemical drugs inhibiting CA IX function 
There exist many chemical compounds inhibiting CA IX catalytic activity. Most of them belong to 
one of two main classes: metal complexing anionic compounds or sulfonamides binding to the 
Zn2+-ion in the active site of carbonic anhydrases (Figure  1.13 A) (Abbate, Casini et al. 2004; Weber, 
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Casini et al. 2004; Di Fiore, De Simone et al. 2005; Menchise, De Simone et al. 2005; Alterio, 
Vitale et al. 2006; Di Fiore, Pedone et al. 2006) (reviewed in (Pastorekova, Parkkila et al. 2004)). 
Mann and Keilin were the first ones giving evidence that sulfonamides inhibit carbonic anhydrases 
(Mann and Keilin 1940). This was the beginning for the discovery of many different sulfonamides 
inhibiting CA IX function. Most of them are not selective for CA IX but recognise also other 
isoforms, although with different affinities (Weber, Casini et al. 2004; Di Fiore, De Simone et al. 
2005; Menchise, De Simone et al. 2005; Alterio, Vitale et al. 2006; De Simone, Vitale et al. 2006; 
Di Fiore, Pedone et al. 2006). Unspecific binding and inhibition of other isozymes with important 
functions for normal cell growth are major drawbacks of chemical drugs targeting CA IX. There 
exist several strategies to achieve selectivity. One strategy is the restriction of drug activation in 
hypoxic regions. This is thought to minimize cross-reactivity to other isoforms expressed in normal 
tissue. Restriction can be achieved by hypoxia-activatable prodrugs, e.g. bulky dimeric 
sulfonamides not able to bind the active site of carbonic anhydrases. These bulky sulfonamides are 
stabilized with disulfide bonds, which are reduced under conditions found in tumours leading to the 
corresponding thiols inhibiting CA IX activity (De Simone, Vitale et al. 2006). Another strategy to 
avoid cross-reactivity with other carbonic anhydrase isoforms expressed under hypoxic conditions 
is to screen compounds for selective inhibition of CA IX over other isoforms, e.g. CA II (De 
Simone, Vitale et al. 2006). A third approach for selectivity of inhibitors is to make them 
membrane-impermeant, e.g. by a positive charge (Scozzafava, Briganti et al. 2000; Menchise, De 
Simone et al. 2005). Even though a lot of effort is taken to make chemical inhibitors specific for 
CA IX, there is still a lot of work needed.  
The first carbonic anhydrase inhibitors were used before it was even known that there exist so 
many isozymes with important physiological function. Nevertheless, sulfonamides became widely 
accepted because of generally favourable outcome, e.g. as anti-glaucoma agents and diuretics. The 
sulfonamide acetazolamide is one of the best studied classical carbonic anhydrase inhibitors used in 
clinics (under the trademark diamox; Figure  1.13 B). It was originally used as antiglaucoma agent. 
Acetazolamide has a lot of side effects because it inhibits various isozymes and needs to be applied 
systemically. Many other carbonic anhydrase inhibitors have the same drawbacks (reviewed in 
(Pastorekova, Parkkila et al. 2004)). 
Some carbonic anhydrase inhibitors are even not selective for carbonic anhydrases (Abbate, Casini 
et al. 2004; Weber, Casini et al. 2004; Di Fiore, Pedone et al. 2006). They are also used in the 
therapy of a number of neurological and neuromuscular syndromes, e.g. epilepsy and ataxia 
(reviewed in (Pastorekova, Parkkila et al. 2004)). 
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Figure  1.13: Sulfonamides. (A) Sulfonamides are commonly used carbonic anhydrase inhibitors containing a 
sulfonamide group. (B) The sulfonamide acetazolamide is a broad range carbonic anhydrase inhibitor used in clinics. 
 
 
1.4.2 Antibodies against CA IX 
Monoclonal antibodies (MAbs) specifically reacting with TAA are important tools for detection 
and therapy of cancers. By selectively targeting tumour cells they have potential applications in 
tumour visualization as well as delivery of therapeutic moieties, e.g. radioisotopes, drugs or toxins 
(reviewed in (Kuroki, Huang et al. 2006)). Independently, two antibodies against TAA in different 
tumours were identified: M75 against a cervical-carcinoma associated antigen (Pastorekova, 
Zavadova et al. 1992) and G250 against a RCC-associated antigen (Oosterwijk, Ruiter et al. 1986). 
Only later, these TAA were shown to be CA IX.  
The antibody M75 was described by Pastorekova et al. It was first found as antibody against the 
quasi-viral agent MaTu, shown to be a two-component system consisting of the viral protein MX 
(p58X) from vesicular stomatitis virus and endogenous MN later shown to be identical to CA IX 
(Pastorekova, Zavadova et al. 1992). M75 recognizes a linear epitope in the PG domain of CA IX 
which is unique to the CA isoform IX. The epitope of M75 consists of a sixfold tandem repeat of 
six aa (aa 61–96) forming 4 identical (GEEDLP) and two slightly different (SEEDSP and 
REEDPP) tandem repeats with a minimal serologically active sequence provided by PGEEDLP 
(Zavada, Zavadova et al. 2000). Recognition of a linear epitope enables M75 to recognize both 
native and denatured antigen and makes it useful for a broad range of applications. 125I-labelled 
M75 can be used for tumour visualization. It specifically accumulates in HT29 xenografts in nude 
athymic mice despite predominant CA IX expression in perinecrotic regions with low accessibility 
(Chrastina, Zavada et al. 2003). HT29 provides a general model for hypoxic tumours. M75 
therefore is a promising tool for targeting of hypoxic tumours (Chrastina, Zavada et al. 2003).  
The antibody G250 was selected by Oosterwijk et al. by using the antibody hybridoma technology 
with specificity for a RCC-associated antigen (Oosterwijk, Ruiter et al. 1986). The G250 antigen 
was later shown to be identical to CA IX (Grabmaier, Vissers et al. 2000). The G250 antigen is 
expressed in most RCC as well as in a couple of non-RCC carcinomas (Oosterwijk, Ruiter et al. 
1986). The epitope of G250 is not known. It is supposed to be a sterical epitope limiting the use of 
G250 in some molecular biology methods where recognition of the denatured protein is required. 
(A) (B) 
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G250 (Bleumer, Knuth et al. 2004) as well as 131I-G250 (Divgi, Bander et al. 1998; Steffens, 
Boerman et al. 1999; Brouwers, Mulders et al. 2005) was tested in phase I and II clinical trials 
(Table  1.3). Currently, there is in an ongoing phase III clinical trial for tumour therapy .To avoid 
induction of human anti-mouse antibodies, a chimeric variant of G250 was constructed (Velders, 
Litvinov et al. 1994). G250 is used under the trademark rencarex® (WX-G250) by Wilex. The 
antibody is well tolerated (Bleumer, Knuth et al. 2004) but therapeutic efficacy is controversial 
(Divgi, Bander et al. 1998; Steffens, Boerman et al. 1999; Bleumer, Knuth et al. 2004; Brouwers, 
Mulders et al. 2005). However, 131I-G250 is a useful clinical tool for tumour imaging (Oosterwijk, 
Bander et al. 1993; Divgi, Bander et al. 1998) and 124I-cG250 antibody is successfully used as a 
PET tracer to identify clear-cell renal carcinoma with a 100% positive predictive value (Divgi, 
Pandit-Taskar et al. 2007). 
Since in vitro CA IX can be upregulated by IFN- and IFN-in some cell lines (Brouwers, Frielink 
et al. 2003), a combination therapy with interferons is thought to enhance therapeutic efficacy. 
Additionally IL-2 does upregulate G250 mediated antibody dependent cellular cytotoxicity 
(ADCC) in vitro (Liu, Smyth et al. 2002). Therefore, several studies tried to combine the ability of 
G250 for tumour targeting with immuno-modulating agents (e.g. IL-2 in clinical trials (Bleumer, 
Oosterwijk et al. 2006; Davis, Liu et al. 2007)) or with toxic moieties (e.g. TNF in preclinical 
studies (Bauer, Oosterwijk-Wakka et al. 2009)).  
 
Table  1.3: Clinical studies using G250. Overview showing some of the clinical studies using G250 as unlabelled or 
131I labeled antibody alone or in combination with IL-2. Many clinical studies using G250 have been performed but its 
clinical relevance is discussed. CR: complete response, SD: stable disease, PD: progressive disease, PR: partial response. 
Adapted from (Stillebroer, Mulders et al. 2010) 
Reference Therapy CR/PR/SD/PD CR/PR/SD/PD 
duration 
Special 
features 
(Bleumer, Knuth et al. 2004) unlabeled cG250 1 CR; 1 PR; 8 SD; 
26 PD 
1-20+ weeks phase II 
(Bleumer, Oosterwijk et al. 
2006) 
unlabeled cG250 + low 
dose IL-2 
2 PR; 6 SD; 27 PD 24+ weeks phase II 
(Davis, Liu et al. 2007) unlabeled cG250 / 131I-
cG250 + low dose IL-2 
1 SD; 8 PD 16-22+ weeks pilot study 
(Divgi, Bander et al. 1998) 131I-mG250 17 SD; 16 PD 2-3 months phase I / II 
(Steffens, Boerman et al. 
1999) 
131I-cG250 1 PR; 1 SD; 10 PD 3 and 9+ months phase I 
(Brouwers, Mulders et al. 
2005) 
131I-cG250 5 SD; 22 PD 3-12 months two high dose 
treatments 
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1.5 AIM OF THE THESIS 
Many solid tumours are difficult to treat. Especially renal cell carcinomas (RCC) are often resistant 
to radiotherapy. Therefore, new therapies are needed. One approach is to specifically target tumour 
associated antigens (TAA). CA IX is a promising TAA for tumour targeting and therapy, since it is 
predominantly expressed in tumour tissue and has an impact on tumour growth through its catalytic 
activity regulating tumour pH. Several sulfonamides and anionic compounds are available, 
inhibiting CA IX activity. Their major drawback is unspecific binding and broad inhibition of 
many different carbonic anhydrase isozymes. In contrast, antibodies are very specific. Up to date, 
mainly two antibodies (M75 and G250) are used to target CA IX in tumour tissue. Unfortunately, 
both of them are not able to inhibit CA IX activity and their clinical use is controversial. In order to 
achieve new promising therapies, it is important to combine the inhibition potential of chemical 
drugs with the specificity of antibodies.  
The aim of this work was to combine target specificity of antibodies with biological activity against 
CA IX enzymatic activity. The goal was to select new antibodies against CA IX and characterize 
them in more detail. A major focus was to examine the physiological effect of the here selected 
antibodies and to find antibodies inhibiting CA IX activity. To have a simple test system, cross-
reactivity of such antibodies with the murine isoform of CA IX was furthermore intended. 
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2 MATERIAL AND METHODS 
2.1 MATERIAL 
2.1.1 Primers 
Primers were used for DNA fingerprint (fingerprint_fwd; fingerprint_back) and sequencing (pCES 
fwd_LC; pCES rev_HC) of pCES1 derived constructs as well as for colony PCR 
(pEE 12.4_1901_rev) and cloning (all other primers) of pEE 12.4 derived constructs (Table  2.1). 
 
 
 
Table  2.1: Primers. The sequence of primers used in this work is listed. Orange: overlap with pCES1 leading to a 
universal primer for cloning from this vector, red: overlap with specific sequence of variable domains, blue: overlap 
between two subsequent primers, underlined: restriction sites indicated in the corresponding primer name (DraIII or 
RsrII). HC: heavy chain, LC: light chain. 
Primer designation Primer sequence  
fingerprint_back 5' - agc gga taa caa ttt cac aca gg - 3' 
fingerprint_fwd 5' - ttt gtc gtc ttt cca gac gtt agt - 3' 
HC_Dra_3' 5' - agg cgc aga ggc cgg cca cgg tgt gcc atc tta ccg ctt gag acg gtg ac - 3' 
HC_Dra_5'_MSC 8 5' - tcc act cct gtg tct tct cta cag gcg tcc aca gcc agg tgc agc tac - 3' 
HC_Dra_5’_MSC 11 5' - tcc act cct gtg tct tct cta cag gcg tcc aca gcg agg tcc agc tgg - 3' 
HC_Dra_5' 5' - cca tcg aag cca gtc acc cag tga agg ggg ctt cca tcc act cct gtg tc - 3' 
LC_Rsr_3' 5' - agg atc ttt aat taa cgg acc gct act cac gta gga cgg tca gct tgg tc - 3'  
LC_Rsr_3'_MSC 11 5' - agg atc ttt aat taa cgg acc gct act cac gct tga tct cca cct tgg tc - 3'  
LC_Rsr_5'_MSC 3 5' - t gtc ttc tct aca ggc gtg cac agc cag tct gtc gtg acg cag c - 3' 
LC_Rsr_5'_MSC 8 5' - t gtc ttc tct aca ggc gtg cac agc cag gct gtg ctg act cag c - 3' 
LC_Rsr_5'_MSC 11 5' - t gtc ttc tct aca ggc gtg cac agc gaa att gtg ttg acg c - 3' 
LC_Rsr_5' 5' - cag tca agg ggg cgg acc gct tcc atc cac tcc tgt gtc ttc tct aca gg 
pCES fwd_LC 5' - agc gga taa caa ttt cac aca gg - 3' 
pCES rev_HC 5' - gga agt agt cct tga cca - 3' 
pEE 12.4_1901_rev 5' - cgg cga cat ttt caa tat gc - 3' 
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2.1.2 Antibodies 
Primary and secondary antibodies used in this work are listed in Table  2.2 and Table  2.3, respectively. 
 
Table  2.2: Primary antibodies. Primary antibodies used in this work are shown. The target of the antibodies as well as 
their source is indicated. In the rest of the work antibodies are referred to by their short name. 
antibody designation short name target source 
mAb anti-c-myc [9-E10] anti-Myc Myc-tag Novus Biologicals 
Penta-HisTM antibody, mouse monoclonal 
IgG1 
anti-His His-tag QIAGEN 
ESC 11 IgG ESC 11 IgG muFAP and huFAP produced in-house *) 
CA IX (M-100), rabbit polyclonal IgG M-100 murine CA IX Santa Cruz 
chG250 chG250 human CA IX kindly provided by E. 
Oosterwijk 
M75 M75 human CA IX kindly provided by E. 
Oosterwijk 
anti-hCarbonic Anhydrase II, purified rat 
monoclonal IgG2A 
anti-CA II human CA II R&D Systems 
anti-mTNF-, mTNF- affinity purified goat 
IgG 
anti-muTNF murine TNF- R&D Systems 
anti-hTNF-, TNF- affinity purified goat 
IgG 
anti-huTNF human TNF- R&D Systems 
Hypoxyprobe™-1 Kits 4.3.11.3. mAb hypoxy-probe pimonidazole hpi 
ChromePure human IgG, whole molecule huIgG - Jackson ImmunoResearch 
*) E. Fischer, manuscript in preparation  
 
Table  2.3: Secondary antibodies. Secondary antibodies used in this work are shown. The target of the antibodies as well 
as their source is indicated. In the rest of the work antibodies are referred to by their short name. 
antibody designation short name target source 
R-Phycoerythrin-conjugated Streptavidin Strep-PE Biotin Jackson ImmunoResearch 
Streptavidin-POD conjugate  Strep-POD Biotin Roche 
DyLightTM 549-conjugate Streptavidin Strep-DyLigth 549 Biotin Jackson ImmunoResearch 
Cy™5-conjugated AffiniPure F(ab')2 
fragment goat anti-human IgG, F(ab')2 
fragment specific 
anti-huFab-Cy5 human F(ab’)2 Jackson ImmunoResearch 
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Polyclonal rabbit anti-goat 
immunoglobulins/ biotinylated 
anti-goat-biotin goat IgG Dako Cytomation 
R-Phycoerythrin-conjugated AffiniPure 
F(ab’)2 fragment goat anti-human IgG, 
F(ab')2 fragment specific 
anti-huFab-PE human F(ab’)2 Jackson ImmunoResearch 
Biotin-SP-conjugated AffiniPure F(ab’)2 
fragment goat anti-human IgG, F(ab')2 
fragment specific 
anti-huFab-biotin human F(ab’)2 Jackson ImmunoResearch 
Peroxidase-conjugated AffiniPure Goat 
Anti-Human IgG, F(ab')2 Fragment 
Specific 
anti-huFab-POX human F(ab’)2 Jackson ImmunoResearch 
polyclonal goat anti-mouse 
immunoglobulins/HRP 
anti-m-HRP mouse IgG Dako Cytomation 
Biotin-SP-conjugated AffiniPure Rabbit 
Anti-Mouse IgG (H+L) 
anti-m-biotin mouse IgG 
(H+L) 
Jackson ImmunoResearch 
Biotin-SP-conjugated AffiniPure F(ab')2 
Fragment Goat Anti-Rabbit IgG, F(ab')2 
Fragment Specific 
anti-rabbit-biotin rabbit F(ab’)2 Jackson ImmunoResearch 
goat anti-rabbit IgG-HRP anti-rabbit-HRP rabbit IgG SantaCruz 
Biotin-SP-conjugated AffiniPure Donkey 
Anti-Rat IgG (H+L) 
anti-rat-biotin rat IgG (H+L) Jackson ImmunoResearch 
 
 
2.1.3 Plasmids 
Two plasmids were used: pCES1 and pEE12.4. The pCES1 plasmid (kindly provided by Dyax, 
MA, USA) displays the Fab antibody library used (see  2.2.2 Selection of antibodies by phage display). It 
can be used to express phages presenting Fab antibodies coupled to the gene III protein on their 
surface (see  2.2.3 Phage production) or to produce soluble Fab antibodies (see  2.2.7 Fab production) (de 
Haard, van Neer et al. 1999). A schematic representation of pCES1 is shown in Figure  2.1. At the 3’ 
end a hexa-histidine-tag followed by a myc-tag is attached to simplify detection and purification of 
Fab antibodies. The plasmid contains an ampicillin-resistance cassette.  
The plasmid pEE 12.4 (LONZA Biologicals, Basel, Switzerland) is designed for expression of 
IgGs in myeloma cell lines. It contains the glutamine synthetase (GS) gene and an ampicillin-
resistance cassette as selection marker.  
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gene III
pLacZ
CS
rbs
ApaLI   XhoI AscI
*H6 tagCH1
SfiI   BstEII NotI
S
rbs
PstI
 
Figure  2.1: Phagemid vector pCES1 for display of antibody Fab fragments. Schematic representation of pCES1. The 
operon is under the control of the LacZ promotor (pLacZ). Rbs: ribosomal binding site, S: signal sequence, H6: hexa-
histidine-tag, tag: myc-tag, *: amber stop codon enabling production of Fab antibodies. Cloning sites indicated are unique 
in pCES1. From (de Haard, van Neer et al. 1999). 
 
The plasmids selected and cloned in this work are all derived from pCES1 or pEE 12.4 (Table  2.4). 
pCES1-MSC 1-12 were selected by phage display and used to produce phages displaying Fab 
antibodies MSC 1 - 12 or to produce Fab antibodies MSC 1-12. pEE 12.4 MSC 3, 
pEE 12.4 MSC 8, pEE 12.4 MSC 11, pEE 12.4 MSC 3-huTNF, pEE 12.4 MSC 3-muTNF, 
pEE 12.4 MSC 11-huTNF and pEE 12.4 MSC 11-muTNF were cloned in this work and used for 
expression of the corresponding IgG or F(ab)2-TNF constructs. 
 
Table  2.4: Plasmids. List of plasmids selected by phage display (derived from pCES1) and plasmids cloned in this work 
(derived from pEE 12.4). All plasmids contain the ampicillin-resistance cassette as selection marker. Plasmids derived 
from pEE 12.4 contain in addition the GS gene as selection marker for cell culture. For cloning strategies, see  2.2.14 
Cloning of IgGs and TNF-constructs. HC: heavy chain, LC: light chain. 
plasmid designation description 
pCES1-MSC 1-12 pCES1 containing the variable domains of HC and LC of the selected Fab antibodies 
MSC 1 - 12 
pEE 12.4 plasmid for expression of IgGs in myeloma cell lines 
pEE 12.4 MSC 3 pEE 12.4 containing the variable domains of HC and LC of MSC 3 
pEE 12.4 MSC 8 pEE 12.4 containing the variable domains of HC and LC of MSC 8 
pEE 12.4 MSC 11 pEE 12.4 containing the variable domains of HC and LC of MSC 11 
pEE 12.4 MSC 3-muTNF pEE 12.4 containing the variable domains of HC and LC of MSC 3, with the Fc 
region replaced by murine TNF 
pEE 12.4 MSC 3-huTNF pEE 12.4 containing the variable domains of HC and LC of MSC 3, with the Fc 
region replaced by human TNF 
pEE 12.4 MSC 11-muTNF pEE 12.4 containing the variable domains of HC and LC of MSC 11, with the Fc 
region replaced by murine TNF 
pEE 12.4 MSC 11-huTNF pEE 12.4 containing the variable domains of HC and LC of MSC 11, with the Fc 
region replaced by human TNF 
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Table  2.5: Bacterial media. The composition of the indicated bacterial media is listed. For cloning LB medium was 
used, for phage display and expression of Fab antibodies 2xTY media were used. 
Bacterial media composition  
LB 10 % (w/v) 
5 % (w/v) 
10 % (w/v) 
BactoTM Tryptone 
yeast extract 
NaCl 
LB agar plates  
1.5 % (w/v) 
LB 
DifcoTM Agar 
2xTY 16 % (w/v) 
10 % (w/v) 
5 % (w/v) 
BactoTM Tryptone 
yeast extract 
NaCl 
2xTY-AG  
0.1 mg/ml 
2 % (w/v) 
2xTY 
ampicillin 
glucose 
2xTY-AK  
0.1 mg/ml 
25 g/ml 
2xTY 
ampicillin 
kanamycin 
2xTY-AG agar plates  
1.5 % (w/v) 
2xTY-AG 
DifcoTM Agar 
 
2.1.4 Bacteria, phages and bacterial media 
Premade Z-competent E.coli cells (TG-1; Zymo Research) were used for phage display (see  2.2.2 
Selection of antibodies by phage display) and expression of Fab antibodies (see  2.2.7 Fab production). For 
cloning of IgGs and TNF-constructs, One Shot® TOP10 Competent cells (TOP10; Invitrogen) were 
used. Bacterial media are indicated in Table  2.5. 
M13K07 (New England Biolabs) containing a kanamycin resistance cassette was used as helper 
phage (see  2.2.2 Selection of antibodies by phage display and  2.2.3 Phage production). 
 
2.1.5 Cell lines and cell culture media 
Experiments were performed on human cell lines stably transfected with a plasmid encoding 
CA IX or with empty vector (HCT 116-CA IX / HCT 116-EV; SKRC 17 MW1 cl4 / SKRC 17), on 
pVHL deficient renal clear cell carcinomas expressing CA IX at different levels (SKRC 1, 
SKRC 52 and SKRC 59) and on HeLa cells upregulating CA IX expression under hypoxia (see 
 2.2.1 Cell culture), upon stimulation with hypoxia mimicking agents (see  2.2.1 Cell culture) and under 
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conditions of high density. HEK 293 cells were used for transient transfections (see  2.2.15 Transient 
and stable transfection). Human cell lines with the respective culture medium (Table  2.6) are given in 
Table  2.7. 
Murine cell lines used are listed in Table  2.8. C51 and CT26 upregulate CA IX expression upon 
induction under hypoxic conditions or after incubation with hypoxia mimicking agents (see  2.2.1 
Cell culture). Wehi S cells were used for TNF-assays (see  2.2.22 TNF assay). NSO cells were used for 
stable transfection (see  2.2.15 Transient and stable transfection). The stable transfections produced in 
this work express human IgG or F(ab)2-TNF constructs. 
 
Table  2.6: Cell culture media. The composition of cell culture media is indicated. 
culture media composition  
D10  
10 % (v/v) 
100 U / 100 g/ml 
DMEM 
FBS 
penicillin-streptomycin 
D10 -m  
50 M  
D10 
-mercaptoethanol 
Dfreeze 90 % (v/v) 
10 % (v/v) 
FBS 
DMSO 
Dsel  
10 % (v/v) 
2 % (v/v) 
10 M 
100 U / 100 g/ml 
DMEM w/o glutamine 
dialyzed FBS 
GS-supplement (50x) 
MSX 
penicillin-streptomycin 
R10  
10 % (v/v) 
100 U / 100 g/ml 
RPMI 
FBS 
penicillin-streptomycin 
R10_6.3  
10 % (v/v) 
30 mM 
1 % (v/v) 
1 % (v/v) 
set pH to 6.3 
RPMI w/o sodium hydrogen carbonate 
dialyzed FBS 
MES 
HT-supplement (100x) 
antibiotic antimycotic solution (100x) 
R10_7.3  
10 % (v/v) 
30 mM 
1 % (v/v) 
1 % (v/v) 
set pH to 7.3 
RPMI w/o sodium hydrogen carbonate 
dialyzed FBS 
HEPES 
HT-supplement (100x) 
antibiotic antimycotic solution (100x) 
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Table  2.7: Human cell lines. Different cancer cell lines were used to express CA IX (transfected cell lines, pVHL-
deficient cell lines and cell lines upregulating CA IX under hypoxic conditions) and cultured using the indicated media. 
For transient transfections HEK 293 cells were used. 
Human cell lines culture media description origin 
HCT 116-CA IX D10 human colon carcinoma P. Swietach 
HCT 116-EV D10 human colon carcinoma P. Swietach 
HEK 293 D10 + 0.2 mg/ml G418 human embryonic kidney ATCC 
HeLa D10 human cervical cancer ATCC 
MCF-7 D10 human breast cancer cell line Ludwig Cancer Institute 
SKRC 1 R10 human renal clear cell carcinoma Ludwig Cancer Institute 
SKRC 17 R10 human renal clear cell carcinoma E. Oosterwijk 
SKRC 17 MW1 cl4 R10 + 0.4 mg/ml G418 human renal clear cell carcinoma E. Oosterwijk 
SKRC 52 R10 human renal clear cell carcinoma Ludwig Cancer Institute 
SKRC 59 R10 human renal clear cell carcinoma Ludwig Cancer Institute 
 
 
CHO-MSC 3 and CHO-MSC 8 cells were produced by stable transfection of CHO cells at the 
Ludwig Cancer Institute in Melbourne, Australia, for large scale production of MSC 3 and MSC 8 
IgG (Table  2.9).  
 
 
Table  2.8: Murine cell lines. C51 and CT26 cell lines were used to express CA IX under hypoxic conditions and 
cultured using the indicated media. For stable transfections NSO cells were used leading to NSO-derived cell lines. TNF-
sensitive Wehi S cells were used in TNF-assays. 
Murine cell lines culture media description origin 
C51 D10 murine colon carcinoma M. Rudin 
CT26 D10 -M murine colon carcinoma H. Nishikawa 
NSO D10 murine myeloma LONZA 
NSO-MSC 11 Dsel NSO producing MSC 11 IgG produced in this work 
NSO-MSC 11-
muTNF 
Dsel NSO producing MSC 11-muTNF produced in this work 
NSO-MSC 3-
muTNF 
Dsel NSO producing MSC 3-muTNF produced in this work 
Wehi S R10 murine fibrosarcoma Ludwig Cancer Institute 
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Table  2.9: Hamster cell lines. For large scale production of IgG, CHO cells were stably transfected with 
pEE 12.4 MSC 3 and pEE 12.4 MSC 8. 
Hamster cell lines culture media description origin 
CHO D10 chinese hamster ovary cells Ludwig Cancer Institute 
CHO-MSC 3 Dsel CHO producing MSC 3 IgG produced in Melbourne 
CHO-MSC 8 Dsel CHO producing MSC 8 IgG produced in Melbourne 
 
2.1.6 Chemicals and kits 
Chemicals and kits used are listed in Table  2.10. 
 
Table  2.10: Chemicals and kits. Chemicals and kits are listed with the respective companies. In brackets commonly 
used abbreviations or chemical formulas are indicated. 
Chemicals / Kits purchased from 
1 kb ladder New England Biolabs 
100 bp ladder New England Biolabs 
acetazolamide (ATZ) Sigma-Aldrich 
acetic acid, 99 % Sigma-Aldrich 
acrylamide - Rotiphorese® Gel 30 (37, 5:1)  Roth 
agarose Promega 
ammonium chloride (NH4Cl) Sigma-Aldrich 
ammonium persulfate (APS) Sigma-Aldrich 
ampicillin sodium salt (Amp) Sigma-Aldrich 
antibiotic antimycotic solution (100x) Sigma-Aldrich 
BactoTM Tryptone BD Biosciences 
BCATM Protein Assay Reagent Thermo Scientific 
BD Cytofix/CytpopermTM BD Biosciences 
BD Perm/WashTM BD Biosciences 
bovine serum albumin (BSA) Thermo Scientific 
Brilliant Blue R Sigma-Aldrich 
bromphenol blue sodium salt Merck 
BstNI New England Biolabs 
calcium chloride (CaCl2) Sigma-Aldrich 
CaptureSelect Fab kappa affinity matrix  BAC 
cobalt chloride (CoCl2) Fluka 
collagen type I BD Biosciences 
Complete, EDTA free (Proteinase inhibitor) Roche 
crystal violet Roth 
DHPE-fluorescein Invitrogen 
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dialysed fetal bovine serum (dialysed FBS) Sigma-Aldrich 
DifcoTM 2xYT (Yeast Extract Tryptone) Medium BD Biosciences 
DifcoTM Agar, granulated BD Biosciences 
dimethyl sulfoxide (DMSO) Sigma-Aldrich 
dimethyloxaloylglycine (DMOG) Frontier Scientific 
disodium hydrogen phosphate (Na2HPO4) Roth 
DL-dithiothreitol (DTT) Sigma-Aldrich 
DMEM Invitrogen 
DMEM w/o glutamine Invitrogen 
DraIII New England Biolabs 
Dynabeads® Protein G Invitrogen 
ECLTM Western Blotting Detection Reagents GE Healthcare 
ethanol (EtOH) Merck 
ethidium bromide (EtBr), 10 mg/ml Sigma-Aldrich 
ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich 
EZ4U Biomedica  
fetal bovine serum (FBS) Invitrogen 
FseI New England Biolabs 
FuGENE HD Transfection Reagent Roche 
G418 Sigma 
glucose DeltaSelect 
glycerol Roth 
glycine Sigma-Aldrich 
GS-supplement (50x) Invitrogen 
HBS-P+ 10x GE Healthcare 
Hepes Invitrogen 
HT-supplement (100x) Invitrogen 
hydrochloric acid (HCl), fuming (37 %) Roth 
imidazole Sigma-Aldrich 
isopropanol Kantonsapotheke Zürich 
isopropyl--D-tiogalactopyranosid (IPTG) Roche 
kanamycin disulfate salt (Kan) Sigma-Aldrich 
magnesium chloride (MgCl2) Sigma-Aldrich 
MES Roth 
methanol Kantonsapotheke Zürich 
Methionine sulphoximine (MSX) Sigma-Aldrich 
milk powder Roth 
normal goat serum (NGS) Vector Laboratories 
NotI New England Biolabs 
Octyl β-D-glucopyranoside (-OG) Sigma-Aldrich 
OptiMEM Invitrogen 
Orange G Sigma-Aldrich 
paraformaldehyde, 4% in PBS (4 % PFA) Kantonsapotheke Zürich 
penicillin-streptomycin Invitrogen 
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Peroxidase Substrate Solution A and B KPL 
PhusionTM Hot Start High–Fidelity DNA Polymerase Finnzymes 
poly L-Lysine Sigma-Aldrich 
polyethylene glycol 6000 (PEG) Sigma-Aldrich 
potassium chloride (KCl) Roth 
potassium D-gluconate Sigma-Aldrich 
potassium dihydrogen phosphate (KH2PO4) Sigma-Aldrich 
Precision Plus ProteinTM DUAL COLOR Standards Biorad 
ProLong® Gold antifade reagent with DAPI Invitrogen 
PvuI New England Biolabs 
QIAGEN Plasmid Midi Kit QIAGEN 
QIAprep Miniprep Kit QIAGEN 
QIAquick Gel Extraction Kit QIAGEN 
rAPid Alkaline Phosphatase Roche 
Rapid DNA Ligation Kit Roche 
Recombinant Human Carbonic Anhydrase II (rhCA II) R&D Systems 
Recombinant Human Carbonic Anhydrase IX (rhCA IX) R&D Systems 
Recombinant Human Carbonic Anhydrase XII (rhCA XII) R&D Systems 
Recombinant Human Carbonic Anhydrase XIV (rhCA XIV) R&D Systems 
Recombinant Mouse Carbonic Anhydrase IX (rmCA IX) R&D Systems 
REDTaqTM ReadyMixTM PCR Reaction Mix Sigma-Aldrich 
RPMI Invitrogen 
RPMI w/o sodium hydrogen carbonate Sigma-Aldrich 
RsrII New England Biolabs 
sodium chloride (NaCl) Fluka 
sodium dodecylsulfate (SDS), 20 % solution Ambion 
sodium hydrogen carbonate (NaHCO3) Sigma-Aldrich 
sulphuric acid (H2SO4), 2 N Roth 
SuperSignal® West Femto Maximum Sensitivity Substrate Thermo Scientific 
Talon® metal affinity resin Clontech Laboratories 
Temed Bio-Rad 
Triethylamine Sigma-Aldrich 
Tris Ultra Roth 
Triton X-100 Sigma-Aldrich 
Trypan blue solution (0.4 %) Sigma-Aldrich 
Tween 20 Fluka 
Yeast extract Sigma-Aldrich 
-mercaptoethanol Sigma-Aldrich 
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2.1.7 Buffer 
Composition of buffers is given in Table  2.11. 
 
Table  2.11: Buffer. Composition of the buffers is indicated. 
1 kb ladder 20 % (v/v) 
20 % (v/v) 
10 % (v/v) 
1 kb ladder 
5x DNA loading buffer 
dH2O 
100 bp ladder 20 % (v/v) 
20 % (v/v) 
10 % (v/v) 
100 bp ladder 
5x DNA loading buffer 
dH2O 
agarose gel, 0.8 – 3 % 2 % (v/v) 
0.8 – 3 % (w/v) 
50x TAE 
agarose 
Amm-NT 
 
 
 
 
 
aerate for 1 h with 5 % CO2 / 95 % N2 
1 mM 
1 mM 
4.5 mM 
10 mM 
12 mM 
100 mM 
30 mM 
CaCl2 
MgCl2 
KCl 
Glucose 
NaHCO3 
NaCl 
NH4Cl 
B-NT 
 
 
 
 
aerate for 1 h with 5 % CO2 / 95 % N2 
1 mM 
1 mM 
4.5 mM 
10 mM 
12 mM 
130 mM 
CaCl2 
MgCl2 
KCl 
Glucose 
NaHCO3 
NaCl 
Coomassie destain 45 % (v/v) 
10 % (v/v) 
45 % (v/v) 
methanol 
acetic acid (99 %) 
dH2O 
Coomassie staining solution 45 % (v/v) 
10 % (v/v) 
0.25 % (w/v) 
45 % (v/v) 
methanol 
acetic acid (99 %) 
Brilliant Blue R 
dH2O 
crystal violet solution 0.05 % (w/v) 
20 % (v/v) 
crystal violet 
EtOH 
DNA loading buffer, 5x 50 % (v/v) 
50 % (v/v) 
0.4 % (w/v) 
1x TAE 
Glycerol 
Orange G 
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HBS-P+ 10 mM 
0.15 M 
0.05 % (v/v)  
Hepes 
NaCl 
Surfactant P20 
Hepes-NT, pH 7.4 
 
 
 
 
set pH to 7.4 
1 mM 
1 mM 
4.5 mM 
10 mM 
10 mM 
130 mM 
CaCl2 
MgCl2 
KCl 
Glucose 
Hepes 
NaCl 
homogenization buffer 15 mM 
35 mM 
105 mM 
20 mM 
20 mM 
NaCl 
KCl 
potassium D-gluconate 
Hepes 
MES 
isopropanol/HCl  
0.4 N 
Isopropanol 
HC 
Lämmli buffer 0.28 M 
0.5 M 
30 % (v/v) 
1 % (v/v) 
0.0012 % (w/v) 
5.5 % (v/v) 
Tris Ultra 
DTT 
glycerol 
SDS (20 %) 
bromphenol blue 
-mercaptoethanol 
lysis buffer 150 mM 
50 mM 
10 mM 
0.70 % 
NaCl 
Tris-HCl, pH 7.4 (1 M) 
MgCl2 
-OG 
MES-NT, pH 6.4 
 
 
 
 
set pH to 6.4 
1 mM 
1 mM 
4.5 mM 
10 mM 
10 mM 
130 mM 
CaCl2 
MgCl2 
KCl 
Glucose 
MES 
NaCl 
MPBS, 2 – 4 %  
2 – 4 % (w/v) 
PBS 
milk powder 
MPBST 150 mM 
10 mM 
1.5 mM 
0.1 – 0.3 % (v/v) 
2 % (w/v) 
NaCl 
Na2HPO4 
KH2PO4 
Tween 20 
milk powder 
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PBS 150 mM 
10 mM 
1.5 mM 
NaCl 
Na2HPO4 
KH2PO4 
PBST, 0.1 - 0.3 % 150 mM 
10 mM 
1.5 mM 
0.1 – 0.3 % (v/v) 
NaCl 
Na2HPO4 
KH2PO4 
Tween 20 
PEG/NaCl 20 % (w/v) 
1.5 M 
PEG 
NaCl 
running buffer 25 mM 
0.1% (v/v) 
200 mM 
Tris Ultra 
SDS (20 %) 
Glycine 
running gel, 10 % (v/v) 42 % (v/v) 
33 % (v/v) 
25 % (v/v) 
0.01 % (v/v) 
0.0005 % (v/v) 
dH2O 
acrylamide (30 %) 
1.5 M Tris/SDS, pH 8.8 
APS 
Temed 
running gel, 12 % (v/v) 35 % (v/v) 
40 % (v/v) 
25 % (v/v) 
0.01 % (v/v) 
0.0005 % (v/v) 
dH2O 
acrylamide (30 %) 
1.5 M Tris/SDS, pH 8.8 
APS 
Temed 
running gel, 8 % (v/v) 48 % (v/v) 
27 % (v/v) 
25 % (v/v) 
0.01 % (v/v) 
0.0005 % (v/v) 
dH2O 
acrylamide (30 %) 
1.5 M Tris/SDS, pH 8.8 
APS 
Temed 
SDS loading buffer (non-reducing gel) 0.28 M 
30 % (v/v) 
1 % (v/v) 
0.0012 % (w/v) 
Tris Ultra 
glycerol 
SDS (20 %) 
bromphenol blue 
stacking gel, 5 % (v/v) 61 % (v/v) 
13 % (v/v) 
25 % (v/v) 
0.01 % (v/v) 
0.0007 % (v/v) 
dH2O 
acrylamide (30 %) 
0.5 M Tris/SDS, pH 6.8 
APS 
Temed 
TAE, 50x 2 mM 
0.25 mM 
0.5 mM 
TRIS Ultra 
acetic acid (99 %) 
EDTA 
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transfer buffer 25 mM 
190 mM 
20 % (v/v) 
Tris Ultra 
Glycine 
methanol 
Tris/NaCl, pH 7.5 25 mM 
0.15 M 
set pH to 7.5 
Tris Ultra 
NaCl 
Tris/SDS, 0.5 M, pH 6.8 0.5 M 
0.4 % (v/v) 
adjust pH to 6.8 
Tris Ultra 
SDS (20 %) 
 
Tris/SDS, 1.5 M, pH 8.8 1.5 M 
0.4 % (v/v) 
adjust pH to 8.8 
Tris Ultra 
SDS (20 %) 
 
Tris-HCl, pH 7.4 1 M 
adjust pH to 7.4 
Tris Ultra 
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2.2 METHODS 
2.2.1 Cell culture 
All cells were grown at 37 °C in a 5 % CO2 incubator in the media indicated in Table  2.7, Table  2.8 
and Table  2.9. Cells were passaged by detachment after incubation with PBS containing 1 mM 
EDTA for 5 – 20 min. Cell numbers were determined after staining cells with trypan blue using a 
Neubauer haemocytometer (Omnilab). For freezing, cells were resuspended in 1 ml freezing 
medium (Dfreeze) and transferred to CryoTubeTM Vials (Nunc). Vials were stored for 2 d in a cell 
freezing box containing isopropanol at –80 °C before transfer to liquid nitrogen (-180 °C). 
For expression of CA IX, cells were induced chemically or in a hypoxic chamber. For chemical 
induction cells were incubated with 1 mM (HeLa) or 2 mM (C51 and CT26) 
dimethyloxaloylglycine (DMOG; stock: 1 M in DMSO) for 48 h at 37 °C in a 5 % CO2 incubator. 
Alternatively, cells were induced with 200 M CoCl2 for 48 h. For hypoxic induction cells were 
incubated for 48 h in an Invivo2 400 hypoxic chamber (Ruskinn Technology) at 0.2 % O2, 5 % 
CO2. 
 
2.2.2 Selection of antibodies by phage display 
For selection of CA IX specific antibodies, a non-immunized phage library expressing Fab 
antibodies was used (see  2.1.3 Plasmids) (de Haard, van Neer et al. 1999). 1013 phages were 
precipitated by adding 1/5 volume PEG/NaCl and incubation for 1 h on ice, centrifuged for 15 min 
at 4’000 rpm and blocked in 1 ml 2 % MPBS for 1 h at room temperature. During phage block, 
Dynabeads® Protein G for preabsorption and subsequent phage display were prepared.  
Dynabeads® Protein G were washed three times with Tris/NaCl, pH 7.5. rhCA IX was 
immunoprecipitated using M75 in a total volume of 300 l Tris/NaCl, pH 7.5 for 1 h at 4 °C and 
the CA IX/M75-complex was incubated for 1 h at 4 °C with Dynabeads® Protein G. For 
preabsorption, M75 antibody alone was incubated with Dynabeads® Protein G. Dynabeads® 
Protein G complexes were removed from the suspension using a magnetic rack and washed four 
times with Tris/NaCl, pH 7.5.  
Blocked phages were added to M75/Dynabeads® Protein G and preabsorbed for 2 h at room 
temperature. M75/Dynabeads® Protein G were removed from the suspension using a magnetic rack 
and the phage containing supernatant was transferred to CA IX/M75/Dynabeads® Protein G and 
incubated for 1 h at room temperature. Phages bound to CA IX/M75/Dynabeads® Protein G were 
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washed 10x with MPBST, 10x with 0.3 % PBST and 3x with PBS using a magnetic rack, and 
subsequently eluted with 1 ml 100 mM triethylamine for 10 min at room temperature. 
CA IX/M75/Dynabeads® Protein G were removed from the suspension using a magnetic rack and 
phage containing supernatant was neutralized by adding 500 l Tris-HCl, pH 7.4.  
E. coli TG-1 were grown in 2xTY medium to an OD600 of 0.5. 1 ml neutralized phages was added 
to 5 ml TG-1 and 4 ml 2xTY and incubated for 30 °C in a water bath at 37 °C. The TG-1/phage 
suspension was centrifuged for 10 min at 4’000 rpm and the pellet containing infected TG-1 was 
resuspended in 1.2 ml 2xTY. The bacteria suspension was plated on two 10 cm 2xTY-AG agar 
plates and bacteria were amplified over night at 30 °C. On the next day TG-1 were collected by 
scraping from the plates, resuspended in 2 TY-AG and an aliquot was frozen with 15 % glycerol at 
-80 °C. 5-15 l of the suspension were inoculated in 50 ml 2xTY-AG at 37 °C with shaking until 
an OD600 of 0.5. Phages were produced using M13K07 as helper phage in a ratio of 20:1 phage to 
bacteria. TG-1/M13K07 suspension was incubated for 30 min at 37 °C in a water bath, centrifuged 
for 10 min at 4’000 rpm and the pellet was resuspended in 25 ml prewarmed 2xTY-AK and grown 
over night at 30 °C on an orbital shaker.  
Four rounds of selection with decreasing antigen concentration were performed (round 1: 90 g 
M75, 30 g rhCA IX and 400 l Dynabeads® Protein G; round 2: 65 g M75, 15 g rhCA IX and 
250 l Dynabeads® Protein G; rounds 3 and 4: 45.5 g M75, 10 g rhCA IX and 150 l 
Dynabeads® Protein G). 
 
2.2.3 Phage production 
Colonies of E.coli TG-1 containing pCES1 encoding the appropriate Fab antibody were inoculated 
in 100 l 2xTY-AG in flat-bottomed 96-well-plates and grown over night at 30 °C on a orbital 
shaker. On the next day 2 l were transferred to a round-bottomed 96-well-plate containing 120 l 
2xTY-AG per well. The plate was sealed with an AirPoreTM Tape Sheet (QIAGEN) to minimize 
evaporation of medium and incubated at 37 °C for 2 h (until OD ≈ 0.5). 40 l 2xTY-AG containing 
2·109 plaque forming units (pfu) M13K07 helper phage were added to each well and incubated for 
30 min at 37 °C. The plate was centrifuged for 10 min at 1700 rpm and all supernatant was 
removed. Cells were resuspended in 120 l 2xTY-AK and grown o/n at 30 °C while shaking. On 
the next day the plate was centrifuged at for 10 min at 1700 rpm and supernatant was used for 
downstream assays like flow cytometry. 
To the original flat-bottomed plate glycerol was added to a final concentration of 15 % and the 
plate was frozen at –80 °C.  
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Table  2.12: PCR conditions for fingerprint. Temperature and time for denaturation, annealing and 
elongation are given. 40 cycles were performed in order to generate many copies of DNA leading 
to strong bands in agarose gel electrophoresis, which is especially important for DNA fingerprint, 
were many small bands are produced. 
 temperature time 
initial denaturation 94 °C 10 min 
denaturation 
annealing 
elongation 
94 °C 
50 °C 
72 °C 
45 s 
45 s 
90 s 
final elongation 72 °C 10 min 
 
2.2.4 DNA fingerprint 
Colonies were screened by PCR using the REDTaqTM ReadyMixTM PCR Reaction Mix according 
to the manufacturer’s instruction. PCR conditions are shown in Table  2.12. For fingerprint of Fab 
antibody sequences in pCES1 primers fingerprint_fwd and fingerprint_back were used for PCR, 
followed by digestion with BstNI for 3 h at 60 °C. Fingerprint of pEE12.4 to confirm correct 
insertion of HC and LC was performed using the corresponding cloning primers for variable 
domain amplification and the amplified DNA was cut with an appropriate multi-cutting restriction 
enzyme. Bands were analyzed on a 3 % agarose gel. 
 
2.2.5 Agarose gel electrophoresis 
Sample DNA was mixed with 5x DNA loading buffer and separated on a 0.8 – 3 % agarose gel in 
1x TAE at 80 – 100 V. For DNA samples obtained by PCR with REDTaqTM ReadyMixTM PCR 
Reaction Mix no 5x loading buffer was needed. 0.5 g 100 bp or 1 kb ladder was used as size 
standard. DNA was visualized under UV using ethidium bromide in a BioDoc-It Imaging System 
(UVP). 
 
2.2.6 Monoclonalisation of bacteria expressing Fab antibodies 
If necessary, bacteria expressing Fab antibodies were monoclonalised by several rounds of 
isolation of plasmid DNA using the QIAprep Miniprep Kit and subsequent transformation into 
E. coli TG-1 according to the manufacturers’ instructions. 
40 cycles 
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2.2.7 Fab production  
Fab antibodies were produced in E. coli TG-1. Overnight cultures of TG-1 were inoculated 1:100 
in 1 l 2xTY-AG and grown at 37 °C. At an OD600 of 0.6-0.9 cultures were induced with 1 mM 
IPTG for 4 h at 30 °C. Cells were centrifuged for 15 min at 4000 rpm and the pellet was frozen at –
20 °C. Soluble Fab antibodies were released from the periplasmic fraction by incubation in 25 ml 
PBS pH 8 containing Complete, EDTA free (Proteinase inhibitor) at 4 °C over night. Crude 
fractions from Fab antibody production were centrifuged 20 min at 8000 g and Fab antibodies 
containing supernatant was incubated with 1 ml Talon® metal affinity resin for 1 h at 4 C, washed 
with 0.1 % PBST, and loaded onto an empty column. The column was washed with 3x column 
volume 0.1 % PBST and Fab antibodies were eluted with PBS, containing 100 mM imidazole. Fab 
antibodies were dialyzed over night at 4 °C against PBS and analyzed by SDS-PAGE followed by 
coomassie staining.  
 
2.2.8 Protein concentration by BCA protein assay or photometry 
Protein concentration was measured with the BCATM Protein Assay Reagent according to the 
manufacturer’s instruction. 5 l sample was incubated with 100 l detection reagent for 30 min at 
37 °C. Absorption at 562 nm was measured in a Wallac Victor2 1420 Multilabel Counter 
(PerkinElmer). BSA was used as standard. 
Alternatively, concentration of purified Fab antibodies was measured in a spectrophotometer 
(Eppendorf) at 280 nm using the Lambert-Beer equation: 
A =  · l · c 
where A is the absorbance,  the extinction coefficient of the protein, l the path length and c the 
concentration. Extinction coefficients for Fab antibodies were calculated using the ProtParam tool 
from ExPASy Proteomics Server (Swiss Institute of Bioinformatics) (Table  2.13). 
 
2.2.9 Whole cell protein extraction 
SKRC 17 MW1 cl4 and SKRC 17 cells from a confluent 75 mm2 cell culture flask were pelleted 
and incubated in 1 ml lysis buffer containing Complete, EDTA free (Proteinase inhibitor) 
according to the manufacturer’s instruction for 20 min at 4 °C while vortexing regularly. The 
sample was centrifuged for 5 min at 13’000 rpm, protein containing supernatant was stored at -
 20 °C and later used for Western blot experiments. 
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Table  2.13: Extinction coefficients. Extinction coefficients for Fab antibodies MSC 1 – 12 were calculated using the 
ProtParam tool from ExPASy Proteomics Server (Swiss Institute of Bioinformatics). 
protein (Fab antibody) extinction coefficient [M-1 cm-1] 
MSC 1 78’560 
MSC 2 75’915 
MSC 3 74’425 
MSC 4 68’465 
MSC 5 81’415 
MSC 6 81’415 
MSC 7 75’915 
MSC 8 93’905 
MSC 9 74’426 
MSC 10 72’935 
MSC 11 66’405 
MSC 12 78’040 
 
2.2.10 SDS-PAGE followed by coomassie staining or immuno blotting 
30 l or 2 g sample (for maximal signal or comparison of different probes, respectively) were 
heated with 1/6 volume Lämmli buffer for 5 min at 95 °C and loaded on an SDS-polyacrylamide 
gel. For non-reducing conditions, SDS loading buffer (w/o DTT and -mercaptoethanol) was used. 
Precision Plus ProteinTM DUAL COLOR Standards was used as molecular weight standard. 
Proteins were collected in a 5 % (v/v) stacking gel at 45 mA and subsequently separated according 
to their molecular weight in a running gel (12 % for reducing conditions, 8% for non-reducing 
conditions) at 65 mA using running buffer. 
The SDS-polyacrylamide gel was stained with coomassie staining solution for 1 h at room 
temperature and afterwards destained in coomassie destain until background was minimal. Gels 
were scanned using a CanoScan LiDE 70 (Canon). 
 
 
Table  2.14: Staining protocol for Western blot analysis. Targets were detected using the indicated staining procedure. 
target 1st antibody 2nd antibody 3rd antibody 
human CA IX M75 (1:1’000) anti-m-HRP (1:1’000) - 
human CA IX MSC 1 – 12 Fab antibody (20 g/ml) anti-Myc (1:1’000) anti-m-HRP (1:1’000) 
human Fab / IgG anti-huFab-POX (1:10’000) - - 
muTNF anti-muTNF (1:1’000) anti-goat-biotin (1:5’000) Strep-POD (1:10’000) 
huTNF anti-huTNF (1:1’000) anti-goat-biotin (1:5’000) Strep-POD (1:10’000) 
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Alternatively, the SDS-polyacrylamide gel was soaked in transfer buffer and transferred for 30 min 
at 10 V to a Protran® nitrocellulose transfer membrane (0.45 m pore size, Whatman®) using a 
Trans-blot® SD semi-dry transfer cell (Bio-Rad). Membranes were blocked with 4 % MPBS for 1 h 
at room temperature and stained against the designated targets with the indicated antibodies added 
in PBS for 1 h at room temperature (Table  2.14). After each antibody, membranes were washed three 
times with 0.1 % PBST. Bands were detected in a ChemiDoc-It Imaging System with BioChemi 
HR Camera (UVP) using ECLTM Western Blotting Detection Reagents or SuperSignal® West 
Femto Maximum Sensitivity Substrate. 
If no resolution of proteins according to molecular weight was necessary, a DotBlot was 
performed. 30-100 l sample was loaded directly on nitrocellulose transfer membranes using a 
loading applicator. Membranes were stained according to the procedure in Western blot analysis. 
 
2.2.11 Flow cytometry 
Fab antibodies and IgGs were analyzed for binding specificities using flow cytometry on antigen 
expressing human and murine cell lines. Bound Fab antibody was detected with anti-Myc, followed 
by anti-m-biotin and Strep-PE. Surface bound IgG was detected using anti-huFab-PE (for huIgG) 
or anti-m-biotin followed by Strep-PE (for muIgG). As control, human samples were stained with 
M75 (1:100) followed by an anti-m-biotin and Strep-PE and murine samples with M-100 (1:100) 
followed by an anti-rabbit-biotin and Strep-PE. All antibodies were used at a dilution of 1:200 if 
not stated otherwise. Incubation was performed in a volume of 100 l for 30 min and samples were 
washed once with PBS between different antibodies. Analysis was performed on a FACScan 
cytometer (BD Biosciences). Geometric mean fluorescence intensity (GMFI) was determined using 
FlowJo 7.5 and signals were normalized to the staining cascade, with the staining cascade set to 
one and the samples shown as n-fold GMFI. 
For titrations, HeLa or SKRC 52 cell lines were induced in 75 cm2 flasks under hypoxic conditions 
(0.2 % O2, 5 % CO2.) for 24 h. Antibodies were added at concentrations ranging from 0 g/ml to 
1 mg/ml and incubated for 2 h in an Invivo2 400 hypoxic chamber (Ruskinn Technology). 
Alternatively, antibodies were added to normoxic cells and incubated at normoxic conditions for 
2 h. Cells were scraped, 10’000 cells per sample were fixed for 30 min in 2 % PFA and stained 
using anti-huFab-PE. Geometric mean fluorescence intensity (GMFI) was determined using 
FlowJo 7.5 and signals were given as percentage of maximal binding. Concentration of half 
maximal binding (EC50) was determined. 
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2.2.12 ELISA 
96-well-microtiter-plates (MaxiSorp Nunc) were coated with 100 ng protein (rhCA IX, rmCA IX, 
rhCA II, rhCA XII or rhCA XIV, respectively) over night at 4 °C, blocked with 2 % MPBS for 1 h 
at room temperature, incubated with 20 g/ml Fab antibody MSC 1-12 for 1 h at room temperature 
and detected with anti-Myc (1:1’000), followed by anti-m-HRP (1:1’000). As loading control, 
samples were stained with anti-His (1:100), followed by anti-m-HRP (1:1’000). For specific 
isoforms, the corresponding antibodies were used: M75 (1:100) for human CA IX followed by anti-
m-HRP (1:1’000), M-100 (1:100) for murine CA IX followed by anti-rabbit-HRP (1:1’000) and 
anti-CA II (1:100) for CA II followed by anti-rat-biotin (1:100) and Strep-POD (1:5’000). 
Peroxidase Substrate Solutions A and B were mixed at a ration of 1:1. 100 l of solution was added 
to each well. As soon as a clear colour change was visible, the reaction was stopped with 50 l 2 N 
H2SO4 and absorbance at 450 nm was measured in a Wallac Victor2 1420 Multilabel Counter 
(PerkinElmer). Signals were normalized to the staining cascade and significance was evaluated 
using a two tailed, paired T-test. 
 
2.2.13 Surface Plasmon Resonance binding assays 
Binding analysis of Fab antibodies to rhCA IX or rmCA IX was performed on a BIAcore T100 
instrument (GE Healthcare, Uppsala, Sweden). CA IX was immobilized at low density on a CM5 
sensor chip (Biacore AB) using amine coupling chemistry, in accordance to the manufacturer’s 
instructions. Fab antibodies at different concentrations (5 to 240 nM) in HBS-P+ buffer were 
injected at a flow rate of 30 µl/min at 25C to analyse binding kinetics. No washing was performed, 
since the coated protein showed to be instable after any tested washing procedure. For the same 
reason, chips were coated at low density. Analysis of the binding curves and the determination of 
rate constants were done using non-linear analysis with BIAcore T100 Evaluation Software V 2.0. 
Double-referenced association and dissociation phase data were locally fit to a 1:1 binding model, 
assuming bulk contribution. 
 
2.2.14 Cloning of IgGs and TNF-constructs 
Variable domains of heavy chain (HC) and light chain (LC) from pCES1 were amplified by two 
subsequent PCR reactions (Table  2.15) using PhusionTM Hot Start High-Fidelity DNA Polymerase 
according to the manufacturer’s instructions (Table  2.16). For MSC 3 HC the DNA sequence was 
codon optimized for a eukaryotic expression system and ordered at geneart. For cloning of F(ab)2-
TNF constructs the TNF insert was cut out from ESC 14-huTNF or ESC 14-muTNF, respectively 
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(Wüest et al., unpublished data). Inserts and pEE 12.4 backbone were digested with DraIII, RsrII or 
FseI/NotI for heavy chain, light chain or F(ab)2-TNF constructs, respectively. The pEE 12.4 
backbone was dephosphorylated using rAPid Alkaline Phosphatase according to the manufacturer’s 
instructions. Insert and pEE 12.4 backbone were both purified via extraction from an agarose gel 
(see  2.2.5 Agarose gel electrophoresis) using the QIAquick Gel Extraction Kit and ligated using the 
Rapid DNA Ligation Kit according to the manufacturer’s instructions. Constructs were transformed 
into One Shot® TOP10 Competent cells according to the manufacturer’s instruction. Cloning was 
analyzed by DNA fingerprint (see  2.2.4 DNA fingerprint) and confirmed by sequencing at 
Microsynth. Positive clones were grown in LB containing 0.1 mg/ml ampicillin over night at 
30 °C. Bacteria suspension was frozen in 15 % glycerol and stored at –80 °C. Plasmids were 
prepared using QIAprep Miniprep Kit or QIAGEN Plasmid Midi Kit. 
 
 
 
Table  2.15: Primers used for cloning of IgG. The primers used for the first and second PCR for amplification of the 
variable domains of the heavy and light chain of selected antibodies are indicated. Sequences of primers are given in 
Table  2.1. 
cloning of … PCR I PCR II 
MSC 3 LC LC_Rsr_5'_MSC 3 & LC_Rsr_3' LC_Rsr_5’ & LC_Rsr_3' 
MSC 8 HC HC_Dra_5'_MSC 8 & HC_Dra_3’ HC_Dra_5' & HC_Dra_3’ 
MSC 8 LC LC_Rsr_5'_MSC 8 & LC_Rsr_3' LC_Rsr_5’ & LC_Rsr_3' 
MSC 11 HC HC_Dra_5’_MSC 11 & HC_Dra_3’ HC_Dra_5' & HC_Dra_3’ 
MSC 11 LC LC_Rsr_5'_MSC 11 & LC_Rsr_3'_MSC 11 LC_Rsr_5’ & LC_Rsr_3'_MSC 11 
 
 
Table  2.16: PCR conditions for amplification of variable domains of HC and LC. Temperature and time for 
denaturation, annealing and elongation are given. For the first PCR 10 cycles were performed followed by a second PCR 
using 15 cycles. PCR products were not purified between the two PCR reactions. 
 temperature time 
initial denaturation 98 °C 30 s 
denaturation 
annealing 
elongation 
98 °C 
57 °C 
72 °C 
10 s 
10 s 
10 s 
final elongation 72 °C 5 min 
 
PCR I: 10 cycles / PCR II: 15 cycles 
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2.2.15 Transient and stable transfection 
HEK 293 cells were transiently transfected using FuGENE HD Transfection Reagent according to 
the manufacturer’s instructions, using 8 l FuGENE HD Transfection Reagent and 2 g DNA. 
Cells were grown in OptiMEM to reduce influence of albumin in downstream Western blot 
experiments. Supernatants were tested after 2-4 d in Western blot and flow cytometry. 
For stable transfection, 40 g DNA was linearized with PvuI for 3 h at 37 °C, followed by heat 
inactivation of PvuI for 20 min at 80 °C. Digestion was confirmed by electrophoresis on a 0.8 % 
agarose gel (see  2.2.5). 107 NSO cells were washed with 20 ml DMEM and resuspended in 700 l 
DMEM. DNA was added to the cells, mixed gently and cells were electroporated in a gene pulser® 
II (Biorad) with a single pulse of 250 V, 400 Fd. Cells were then added to 200 ml DMEM. 
50 l/well cell-suspension was plated in forty 96-well-plates and incubated at 37 °C. Next day, 
150 l Dsel selection medium were added to each well. NSO cells do not express GS and therefore 
can not survive without addition of glutamine. Cells transfected with pEE 12.4 containing the GS 
gene thus can be positively selected. After 4 weeks plates were tested for single clones. 
Supernatants from single clones were tested for IgG production in DotBlot and subsequently in 
Western blot and flow cytometry. Stable cell lines producing MSC 11 IgG, MSC 3-muTNF and 
MSC 11-muTNF were generated. 
 
2.2.16 IgG purification 
Supernatants of transient or stable transfections were sterile filtered and incubated with 0.5 ml 
CaptureSelect Fab kappa affinity matrix per litre for 3 h at 4 °C on a rotator. Samples were 
centrifuges for 3 min at 1500 rpm and washed three times with PBS. IgGs were extracted from the 
beads by incubation with 4 bead volumes of PBS, containing 0.1 M glycine for 1-2 min. After 
centrifugation at 1500 rpm for 3 min, the supernatant was transferred to a new Eppendorf tube and 
was purified by a second centrifugation step. pH of the supernatant was neutralized using 1 M Tris, 
pH 8 (1/10 sample volume) and dialyzed o/n at 4 °C. Samples were aliquoted and shock-frozen in 
liquid nitrogen before storage at –80 °C. 
MSC 3 IgG and MSC 8 IgG were produced and purified by the Ludwig Cancer Institute in 
Melbourne, Australia. 
 
2.2.17 Inhibition of CA IX activity on membrane fragments 
To inhibit CA IX activity in membrane fragments, measurements were performed according to 
Swietach et al (Swietach, Wigfield et al. 2008). In brief, confluent HCT 116-CA IX and HCT 116-
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EV cells were scraped to ice cold water and centrifuged for 7 min at 5000 rpm. Cells were 
resuspended in ice cold homogenization buffer and subjected to two rounds of freeze-thawing 
followed by centrifugation and resuspension of the pellet in fresh homogenization buffer. 660 l 
membrane fragment suspension was added to a 2 ml well-stirred vessel cooled to 2 °C. A narrow 
pH electrode was used to monitor pH. 330 l of CO2-saturated water (produced by aeration of 
dH2O with 5 % CO2 / 95 % N2 for at least 1 h at 2 °C) were added to start the carbonic anhydrase-
catalyzed reaction. pH time-courses were measured. The spontaneous hydration rate was 
determined on membrane–free buffer. Effect of selected antibodies was determined by adding 20 
g/ml Fab antibodies or IgGs to the membrane fragments. As control, 20 g/ml G250, 20 g/ml 
anti-CA II or 100 g/ml acetazolamide (stock: 100 mg/ml in DMSO) were used. For MSC 8 Fab 
and MSC 8 IgG, a dose response experiment was performed using concentrations from 0.1 g/ml 
to 100 g/ml or from 0.1 g/ml to 200 g/ml, respectively. The reaction constant was calculated 
from the pH time-course using a fitting algorithm developed by Swietach et al (Swietach, Patiar et 
al. 2009) and normalized to HCT 116-EV (zero) and activity using HCT 116-CA IX membrane 
fragments (one). 
 
2.2.18 Inhibition of CA IX activity on intact single cells 
CA IX activity was inhibited on intact single cells according to Swietach et al. (Swietach, Patiar et 
al. 2009). HCT 116-CA IX cells were plated on a poly-L-Lysine coated chamber, fitted on an 
inverted Nikon microscope. Cells were exposed to medium containing 50 M DHPE-fluorescein 
for 10 s. The dye was excited at 484 nm by a monochromator and emission was detected at 
520 ± 20 nm with a photomultiplier. Cells were either preincubated for 1 h with Fab fragments and 
IgG at a concentration of 20 g/ml or Fab antibodies were added to the superfusate at a 
concentration of 1 g/ml. As control, 100 g/ml acetazolamide (ATZ, stock: 100 mg/ml in DMSO) 
were added to the superfusate. Cells were superfused with 2 ml/min B-NT or Amm-NT. For 
calibration, Hepes-NT, pH 7.4 and Mes-NT, pH 6.4 were used. Data were acquired at 100 Hz using 
Spike software. The area under the curve was calculated as a measurement for carbonic anhydrase 
IX activity and normalized to ATZ. 
 
2.2.19 Immunofluorescence of tumour tissue 
Sections of C51 tumours (kindly provided by S. Lehmann and M. Rudin, Zürich, Switzerland) were 
fixed in 4 % PFA for 10 min and stained with hypoxy-probe (1:100) and unpurified supernatants of 
transiently transfected HEK 293 cells expressing MSC 3 IgG and MSC 11 IgG at a dilution of 1:20, 
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followed by anti-huFab-Cy5 (1:100). Incubations were performed in a volume of 300 l in PBS 
containing 2 % NGS and 2 % Triton X-100. Between different antibodies, sections were washed 
three times for 10 min in PBS. Sections were embedded using ProLong® Gold antifade reagent 
with DAPI. Pictures were taken on an inverse SP2 Leica microscope with 40x magnification.  
 
2.2.20 Internalization of CA IX detected by immunofluorescence 
Cover slips were coated with 100 g/ml collagen type I in PBS for 1 h at 4 °C. 5’000 cells were 
seeded o/n. CA IX expression was chemically induced using DMOG as described in  2.2.1 Cell 
culture. Cells were stained with 20 g/ml anti-CA IX antibodies (MSC 3, MSC 8) or negative 
control (ESC 11) for 1 h at 4 °C or 37 °C, respectively. Cells were fixed and permeabilized with 
BD Cytofix/CytpopermTM for 30 min at 4 °C. Bound IgG was detected with anti-huFab-biotin 
(1:200) followed by Strep-DyLigth549 (1 g/ml, 1:1’800). Antibodies were dissolved in BD 
Perm/WashTM and incubated for 1 h at 4 °C. Between different antibodies, cover slips were washed 
twice with BD Perm/WashTM. Cover slips were embedded with ProLong® Gold antifade reagent 
with DAPI. Pictures were taken on an inverse SP2 Leica microscope with 40x magnification. 
 
2.2.21 Proliferation assay 
To test inhibition of proliferation by selected antibodies, 10’000 SKRC 52 cells were seeded in 96-
well plates and next day different concentrations of Fab antibodies (up to 1 M) were added. 
Alternatively 100’000 HeLa cells or MCF-7 cells were seeded in a 6-well plate, incubated for 24 h 
in an Invivo2 400 hypoxic chamber (Ruskinn Technology) at 1 % O2 and next day 1 M Fab 
antibody was added. To test inhibition by IgG, 1’000 HeLa, SKRC 17 and SKRC 17 MW1 cl4 or 
SKRC 52 cells were seeded in a 96-well plate and incubated for 1-5 days in an Invivo2 400 hypoxic 
chamber (Ruskinn Technology) at 0.2 % O2 with up to 0.5 M IgG. 1-10 days after addition of Fab 
antibodies or IgGs, proliferation was determined using the EZ4U kit according to the 
manufacturer’s instruction, by staining with crystal violet or by counting the cells. For crystal violet 
staining, cells were washed with PBS and incubated for 10 min at room temperature with crystal 
violet solution. Plates were washed in dH2O and dried. Crystal violet was dissolved in 
isopropanol/HCl and absorbance was measured at 560 nm in the Wallac Victor2 1420 Multilabel 
Counter (PerkinElmer). To assess significance a paired two-tailed T-test was performed. 
To test proliferation under conditions of low pH and low hydrogen carbonate, 1000 SKRC 17, 
SKRC 17 MW1 cl4 or SKRC 52 cells were seeded in 6-well-plates. After attachment of the cells to 
the plate, medium was changed to RPMI w/o hydrogen carbonate at pH 6.3 or 7.3 (R10_6.3 or 
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R10_7.3, respectively) and 20 g/ml IgG or 100 M acetazolamide (stock: 100 mM in DMSO) 
were added. Cells were incubated in an incubator at ambient CO2-partial pressure for 24 h. Medium 
was changed to normal RPMI and cells were grown for another 7 d at 5 % CO2. Colonies were 
counted.  
 
2.2.22 TNF assay 
10’000 Wehi S cells were seeded in 96-well-plates in a volume of 100 l. After attachment of the 
cells to the plate, 100 l supernatant of HEK 293 cells transiently transfected with F(ab)2-TNF 
constructs and serial dilutions of the same were added and incubated over night in the incubator. 
On the next day, cells were stained using the EZ4U kit according to the manufacturer’s instruction 
(with only 10 l of substrate added to 200 l cell culture). Absorbance was measured at 450 nm in 
the Wallac Victor2 1420 Multilabel Counter (PerkinElmer) after 2 h. Significance was assessed 
using a paired, two-sided T-test. 
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3 RESULTS 
3.1 SELECTION OF RHCA IX SPECIFIC FAB ANTIBODIES BY PHAGE 
DISPLAY 
3.1.1 Phage display 
Fab antibodies specific to recombinant human CA IX (rhCA IX) were selected from a large human 
Fab antibody library by phage display. Four rounds of selection were performed on decreasing 
concentrations of antigen. After each selection round, phage pools were tested for specific binding 
to CA IX in flow cytometry on chemically induced HeLa cells (Figure  3.1 A). After selection round 
one, no enrichment of phages specifically recognizing CA IX was detectable, whereas rounds two 
and three both led to an increase in CA IX specific phages. Selection round four did not further 
increased binding of the phage pool to HeLa cells expressing CA IX compared to round three. 
After phage display, single clones were picked and phages were produced. Since every selection 
round leads to the loss of potential binders, phages after round three (88 clones) and four (264 
clones) were used for subsequent screening by flow cytometry on CA IX expressing cells. 16 % of 
the tested phages from round three were able to bind to CA IX, whereas after four rounds of 
selection the fraction was augmented to 23 % (Figure  3.1 B). In total, 75 potential binders were 
identified. 
 
 
 
Figure  3.1: Analysis of phages after selection rounds three and four in flow cytometry. (A) Flow cytometry of phage 
pools. Phage pools after selection rounds one (orange), two (red), three (blue) and four (green) were tested on HeLa cells 
induced with 1 mM DMOG and compared to the staining cascade (black). (B) Flow cytometry of single phage clones. 
Single clones after rounds three and four were tested for the percentage of binding to CA IX expressed on HeLa cells 
induced with 1 mM DMOG. 
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3.1.2 Preliminary analysis of selected Fab antibodies  
The potential binders were used for DNA fingerprint and grouped according to their restriction 
patterns. Fingerprint led to the identification of 22 groups containing distinct restriction patterns, 
with each group consisting of one to 16 clones with identical restriction pattern. One clone of each 
group was used to produce Fab antibodies that were tested for specific binding by flow cytometry. 
Binding of Fab antibodies was tested on HeLa cells chemically induced to express CA IX and 
compared to not induced HeLa cells. Additionally, specific binding of Fab antibodies was tested on 
CA IX expressing SKRC 17 MW1 cl4 cells compared to the parental SKRC 17 cells. This screen 
allowed identifying potential binders specifically recognizing CA IX but no other antigen possibly 
present during the first screen by flow cytometry which was performed on CA IX positive cells 
only. Some potential binders bound also to the negative cell lines and, thus, were excluded from 
further experiments. Furthermore, some binders were excluded, since binding to the positive cell 
line observed in the first screen could not be confirmed. All groups excluded apart from one 
consisted of only one clone. The last group excluded contained two clones with identical restriction 
pattern.  
According to this second screen, only twelve groups selected against CA IX were analysed further. 
One clone of each group was once more subjected to DNA fingerprint analysis (Figure  3.2 A). All 
twelve clones showed a distinct restriction pattern, confirming uniqueness of the selected groups. 
The number of clones per group was determined (Figure  3.2 B). Seven groups contained several 
clones with four groups consisting of more than eight clones, indicating enrichment of phages 
during phage display. One clone of each group was sequenced and, if necessary, clones were 
monoclonalised. Sequencing led to the identification of twelve distinct clones named MSC 1 – 12. 
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Figure  3.2: Fingerprint MSC 1 – 12. (A) Uniqueness of the twelve selected groups named MSC 1 – 12 was confirmed 
in DNA fingerprint using BstNI as multi-cutting restriction enzyme. (B) The number of clones with identical restriction 
pattern in each group MSC 1 – 12 was determined. 
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3.2 CHARACTERIZATION OF MSC 1 – 12 
3.2.1 Production of Fab antibodies 
Fab antibodies MSC 1 – 12 were produced and analyzed in SDS-PAGE followed by coomassie 
staining (Figure  3.3). As control, two Fab antibodies ESC 11 and ESC 14 (raised by E. Fischer and 
T. Wüest, unpublished data) recognizing Fibroblast Activation Protein (FAP) were produced and 
analyzed by SDS-PAGE, too. Coomassie staining confirmed production of all Fab antibodies. 
Heavy chain and light chain of the Fab antibodies were expressed at the expected size (around 25 
kDa) and purity of the Fab antibodies was approved.  
 
3.2.2 Induction of CA IX expression in human cell lines 
CA IX expression can be achieved by stable transfection of cell lines with the ca9 gene, by using 
pVHL deficient cell lines or by inducing cells to express CA IX, either by chemical induction or by 
hypoxic induction in a hypoxic chamber. In pre-tests optimal conditions for CA IX expression were 
determined and chemical induction using CoCl2 and DMOG was compared. Chemical induction 
was optimal to upregulate CA IX in HeLa cells with 200 M CoCl2 for 48 h (Figure  3.4 A) or with 
1 mM DMOG for 48 h (Figure  3.4 B). Induction in the hypoxic chamber was optimal at 0.2 % O2 for 
48 h (Figure  3.4 C). Chemical induction with DMOG led to a sharper peak in the histogram showing 
CA IX expression than the chemical induction with CoCl2. This sharper peak corresponds to a 
more homogeneous expression of CA IX and thus further experiments were performed using 
DMOG.  
 
 
 
Figure  3.3: Coomassie of Fab antibodies MSC 1 – 12. Purity of Fab antibodies MSC 1 – 12 as well as control 
antibodies ESC 11 and ESC 14 was confirmed in SDS-PAGE and subsequent coomassie staining.  
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Figure  3.4: Induction of CA IX expression in HeLa cells. Optimal conditions for induction of CA IX expression in 
HeLa cells were found for (A) chemical induction with 200 M CoCl2, (B) chemical induction with 1 mM DMOG or (C) 
hypoxic induction at 0.2 % O2 in a hypoxic chamber for 48 h each. CA IX expression was detected using M75. grey: 
HeLa cells induced to express CA IX, white: not-induced HeLa cells. 
 
3.2.3 Binding characteristics of MSC 1 – 12 on human cell lines expressing CA IX 
The selected Fab antibodies were tested for specific binding to human CA IX in flow cytometry. 
First Fab antibodies MSC 1 – 12 were tested on SKRC 17 cells transfected with the human ca9 
gene to over-express CA IX as well as on the not transfected parental cell line (Figure  3.5 A). All 
twelve Fab antibodies MSC 1 – 12 revealed a human CA IX-specific binding pattern. They 
specifically bound to cell lines transfected with the ca9 gene but not to the parental cell line. 
Binding was considered specific if geometric mean fluorescence intensity (GMFI) on cell lines 
expressing CA IX was at least three times as big as for the control antibodies ESC 11 and ESC 14. 
Control Fab antibodies ESC 11 and ESC 14 did not recognize either cell line.  
As a model for pVHL-deficiency, renal cell lines SKRC 1, SKRC 52 and SKRC 59 cells were 
used. SKRC 1 does express CA IX only at a very low level, whereas SKRC 59 and SKRC 52 show 
intermediate and high levels of CA IX expression, respectively. In flow cytometry, Fab antibodies 
MSC 1 – 12 did not bind to SKRC 1 expressing only low levels of CA IX, but they bound 
specifically to both SKRC 52 and SKRC 59 cells, while control Fab antibodies ESC 11 and 
ESC 14 did not (Figure  3.5 B). Binding on SKRC 52 led to higher GMFI than flow cytometry on 
SKRC 59, corresponding to higher expression levels of CA IX in SKRC 52 cells.  
Binding of Fab antibodies MSC 1 – 12 to CA IX expressed on HeLa cells chemically induced in 
with DMOG was analyzed by flow cytometry (Figure  3.5 C). All Fab antibodies bound specifically 
to HeLa cells induced to express CA IX, while binding on not induced cells was much lower. 
Control Fab antibodies ESC 11 and ESC 14 did not bind to HeLa cells, regardless of their CA IX 
expression.  
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Figure  3.5: Binding characteristics of Fab antibodies MSC 1 – 12 on human cell lines. Binding of Fab antibodies 
MSC 1 – 12 as well as control Fab antibodies ESC 11 and ESC 14 was tested by flow cytometry on (A) transfected 
SKRC 17 MW1 cl4 (black) vs. parental SKRC 17 (white) cell lines (n = 4), (B) pVHL deficient cell lines SKRC 1 
expressing low (white), SKRC 52 high (black) or SKRC 59 intermediate (grey) amounts of CA IX (n ≥ 4), (C) 
chemically induced (black) or not induced (grey) HeLa cells (n = 5) and (D) HeLa cells induced in a hypoxic chamber 
(black) or under normoxia (grey) (n = 3). Geometric mean fluorescence intensity (GMFI) was calculated and normalized 
to the staining cascade. Mean values of all experiments are shown. The dotted line indicates significant binding, where 
GMFI is three times higher than for controls ESC 11 and ESC 14. 
(A) transfected cell lines 
(B) pVHL deficient cell lines 
(C) chemically induced cells 
(D) hypoxia induced cells 
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Figure  3.6: Ratio showing binding of Fab antibodies on human CA IX induced chemically or by hypoxia. The ratio 
of GMFI on HeLa cells expressing CA IX after chemical induction to GMFI on HeLa cells expressing CA IX after 
hypoxic induction was calculated. The dotted line indicates a ratio of 1.  
 
 
The most physiological model simulating expression of CA IX in cancer tissue with limited oxygen 
supply is provided by HeLa cells induced to express CA IX in a hypoxic chamber. In flow 
cytometry, MSC 1 – 12 bound specifically to hypoxia induced HeLa cells, while binding to not 
induced cells was minimal and control antibodies did not bind at all (Figure  3.5 D).  
Over all human cell lines analyzed, MSC 3 revealed the highest binding to human CA IX followed 
by MSC 1 and MSC 11. Lowest but nevertheless specific binding was observed for MSC 4. 
Since CA IX is thought to have an active conformation under hypoxic conditions only, antibodies 
might show a difference in binding behaviour on cell lines expressing CA IX due to hypoxia or due 
to other factors, e.g. chemical induction or pVHL deficiency. However, if ratios of GMFI on 
chemically induced to hypoxia induced HeLa cells were calculated, ratio were around one for all 
Fab antibodies showing no significant difference in binding to CA IX expressed by chemical or 
hypoxic induction as calculated using an unpaired, two-sided T-test (Figure  3.6). In case that no 
difference could be observed due to short-time expression of the active conformation, one Fab 
antibody, MSC 8, and its corresponding IgG (see  3.2.11 IgG production of selected antibodies) was 
titrated on HeLa cells (data not shown) and SKRC 52 cells (Figure  3.7 A and B) induced in a hypoxic 
chamber or under normoxic conditions. On HeLa cells no EC50 value could be calculated, since 
saturation levels were not reached (data not shown). On SKRC 52 cells, EC50 was in the same 
range on cells induced under normoxic or hypoxic conditions (Figure  3.7 C). For MSC 8 Fab, EC50 
on cells induced under hypoxic conditions was 22.1 g/ml compared to 24.6 g/ml on cells 
induced under normoxic conditions. For MSC 8 IgG, EC50 values were 1.4 g/ml and 1.6 g/ml for 
hypoxic and normoxic conditions, respectively. 
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Figure  3.7: Titration of MSC 8 Fab and MSC 8 IgG on SKRC 52 cells induced under normoxic vs. hypoxic 
conditions. One representative titration for (A) MSC 8 Fab (n = 9) and (B) MSC 8 IgG (n = 4) on SKRC 52 cells induced 
under hypoxic (black) or normoxic (grey) conditions is shown. The dotted line represents half maximal binding. (C) EC50 
values were determined and significant differences were determined using a paired, two-sided T-test. Mean values with 
SEM are shown. 
 
 
 
Figure  3.8: Induction of CA IX expression in C51 cells. Optimal conditions for induction of CA IX expression in C51 
cells were found for (A) chemical induction with 2 mM DMOG or (B) hypoxic induction at 0.2 % O2 in a hypoxic 
chamber for 48 h. CA IX expression was detected using M-100 antibody. Grey: C51 cells induced to express CA IX, 
white: not-induced C51 cells. 
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3.2.4 Induction of CA IX expression in murine cell lines 
Since cross-reactivity with murine CA IX is favourable for later mouse experiments, selected Fab 
antibodies were tested for cross-reactivity to murine CA IX. On murine cell lines, murine CA IX 
can be induced either chemically with DMOG or under hypoxic conditions in a hypoxic chamber. 
Pre-tests showed that for murine cell lines CA IX induction was much weaker than in HeLa cells. 
Optimal conditions were reached using 2 mM DMOG for 48 h (Figure  3.8 A) or induction in a 
hypoxic chamber at 0.2 % O2 for 48 h (Figure  3.8 B). 
 
3.2.5 Binding characteristics of MSC 1 – 12 on murine cell lines expressing CA IX 
The Fab antibodies were tested by flow cytometry on murine C51 (Figure  3.9 A) and CT26 (Figure 
 3.9 B) cells induced chemically with DMOG. Only MSC 1 and MSC 3 showed specific binding. 
Since CA IX expression in murine cell lines was much weaker than in human cell lines, binding 
was considered specific if GMFI of probes was at least twice the GMFI of control antibodies. The 
other Fab antibodies did not bind to murine CA IX. Binding of MSC 7, MSC 9, MSC 11 and 
MSC 12 on C51 was not specific although higher than for control antibodies ESC 11 and ESC 14. 
Specific binding of MSC 1 and MSC 3 to murine CA IX was confirmed by flow cytometry on 
hypoxia induced C51 (Figure  3.9 C). As on C51 chemically induced, binding of MSC 7, MSC 9, 
MSC 11 and MSC 12 was not specific although higher than for control antibodies ESC 11 and 
ESC 14. Flow cytometry on CT26 induced under hypoxia confirmed cross-reactivity of MSC 3 
while binding of MSC 1 was not specific compared to controls ESC 11 and ESC 14 (Figure  3.9 D). 
Over all cell lines and conditions tested, MSC 3 showed highest binding to murine CA IX followed 
by MSC 1. 
Like for human CA IX, murine CA IX might show a different conformation under hypoxic 
conditions leading to possible differences in binding behaviour of cross-reactive antibodies. 
Therefore, ratios of GMFI on chemically induced to hypoxia induced cells were calculated. On 
C51, ratios were around one for all Fab antibodies showing no significant difference in binding to 
CA IX expressed by chemical or hypoxic induction as calculated using an unpaired, two-sided T-
test (Figure  3.10 A). On CT26 cells in contrast, MSC 1 as well as MSC 3 bound significantly better 
to CA IX expressed after chemical induction than to CA IX expressed under hypoxic conditions 
(Figure  3.10 B).  
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Figure  3.9: Binding characteristics of Fab antibodies MSC 1 – 12 on murine cell lines. Binding of Fab antibodies 
MSC 1 – 12 was tested by flow cytometry on (A) C51 cells (n = 4) and (B) CT26 cells (n = 3) induced with 2 mM 
DMOG (black) or not induced (grey) as well as (C) C51 cells (n = 5) and (D) CT26 cells (n = 6) induced in a hypoxic 
chamber (black) or under normoxic conditions (grey). Geometric mean fluorescence intensity (GMFI) was calculated and 
normalized to the staining cascade. The dotted line indicates significant binding, where GMFI is two times higher than 
for controls ESC 11 and ESC 14. 
(A) chemical induction – C51 
(B) chemical induction – CT26
(C) hypoxic induction – C51
(D) hypoxic induction – CT26 
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Figure  3.10: Ratio showing binding of Fab antibodies on murine CA IX induced chemically or by hypoxia. The 
ratio of GMFI on murine cells expressing CA IX after chemical induction to GMFI on murine cells expressing CA IX 
after hypoxic induction was calculated for (A) C51 or (B) CT26. The dotted line indicates a ratio of 1. Significance was 
calculated using an unpaired, two-sided T-test. P-value: * < 0.05. 
 
3.2.6 Binding characteristics of MSC 1 – 12 on recombinant CA IX 
Fab antibodies MSC 1 – 12 were selected by phage display on recombinant human CA IX. Since 
binding of Fab antibodies on recombinant protein might differ from the one on CA IX expressed on 
cell lines, binding of MSC 1 – 12 was analyzed in ELISA on recombinant human (rhCA IX) and 
recombinant murine CA IX (rmCA IX). All twelve Fab antibodies bound specifically to rhCA IX 
(Figure  3.11 A). Binding was considered specific if absorbance at 450 nm (A450) was at least twice 
the value for control Fab antibodies ESC 11 or ESC 14. Interestingly, compared to other Fab 
antibodies MSC 8 Fab showed only weak although specific binding to rhCA IX in ELISA whereas 
binding in flow cytometry was equivalent to the one of other Fab antibodies. Significance of 
binding was calculated using a paired, two-sided T-test (Table  3.1 A). Binding of all twelve Fab 
antibodies on rhCA IX was significant. In ELISA on rmCA IX MSC 1, MSC 3, MSC 5, MSC 7 
and MSC 9 bound specifically to recombinant murine CA IX (Figure  3.11 B). For specific binders 
significance was calculated using a paired, two-sided T-test. While binding of both MSC 1 and 
MSC 3 was significant, binding of MSC 5, MSC 7 and MSC 9 was not significant (Table  3.1 B). 
Apart from MSC 8 showing different binding behaviour on recombinant compared to naturally 
expressed human CA IX, no differences in binding could be detected. ELISA thus confirmed 
binding data obtained by flow cytometry. All binding data are summarized in Table  3.2. 
(B) CT26 
(A) C51 
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Figure  3.11: Binding characteristics of Fab antibodies in ELISA on recombinant CA IX. Binding of Fab antibodies 
MSC 1 – 12 was analysed in ELISA on (A) rhCA IX or (B) rmCA IX. Experiments were repeated at least four times in 
triplicates. Signals were normalized to the staining cascade. For specific binders significance was calculated using a 
paired, two-sided T-test.  P-values compared to ESC 11 are shown: *** < 0.001, ** < 0.01, * < 0.05.  
 
Table  3.1: P-values for MSC 1 – 12 in ELISA on recombinant CA IX. P-values of MSC 1 – 12 compared to the 
control Fab antibodies ESC 11 and ESC 14 were calculated on (A) human and (B) murine recombinant CA IX using a 
paired, two-sided T-test. T-tests were calculated only if binding was considered specific. P-values < 0.05 are considered 
significant. n.s. not significant, light grey < 0.05, grey < 0.01 and dark grey < 0.001, - no specific binding. 
  
ESC 11 
 
ESC 14 
 
ESC 11 
 
ESC 14 
MSC 1 < 0.001 < 0.001 0.0152 0.0122 
MSC 2 < 0.001 < 0.001 - - 
MSC 3 < 0.001 < 0.001 0.0018 0.0017 
MSC 4 < 0.001 < 0.001 - - 
MSC 5 < 0.001 < 0.001 n.s. n.s. 
MSC 6 < 0.001 < 0.001 - - 
MSC 7 0.0011 0.0011 n.s. n.s. 
MSC 8 0.0105 0.0096 - - 
MSC 9 < 0.001 < 0.001 n.s. n.s. 
MSC 10 < 0.001 < 0.001 - - 
MSC 11 < 0.001 < 0.001 - - 
MSC 12 0.0016 0.0018 - - 
(A) human CA IX (B) murine CA IX 
(A) rhCA IX 
(B) rmCA IX 
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Table  3.2: Summary of binding characteristics of MSC 1 – 12 Fab antibodies. Binding characteristics of MSC 1 – 12 
Fab antibodies in flow cytometry and ELISA on human and murine CA IX are indicated. Binding to human CA IX was 
analyzed in flow cytometry on (A) transfected, (B) pVHL deficient and (C) induced human cell lines and (D) in ELISA 
on rhCA IX. Binding to murine CA IX was analyzed (E) in flow cytometry on induced murine cell lines and (F) in 
ELISA on rmCA IX.  Binding was considered specific in flow cytometry on human cell lines if GMFI > 3x GMFI of 
controls, on murine cell lines if GMFI > 2x GMFI of controls and in ELISA if A450 > 2x A450 of controls. + : specific 
binding; (+) : specific but not significant binding; - : not-specific binding. 
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MSC 1 + - + + + + + + + + - + 
MSC 2 + - + + + + + - - - - - 
MSC 3 + - + + + + + + + + + + 
MSC 4 + - + + + + + - - - - - 
MSC 5 + - + + + + + - - - - (+) 
MSC 6 + - + + + + + - - - - - 
MSC 7 + - + + + + + - - - - (+) 
MSC 8 + - + + + + + - - - - - 
MSC 9 + - + + + + + - - - - (+) 
MSC 10 + - + + + + + - - - - - 
MSC 11 + - + + + + + - - - - - 
MSC 12 + - + + + + + - - - - - 
ESC 11 - - - - - - - - - - - - 
ESC 14 - - - - - - - - - - - - 
M75 + + + + + + + + - + - - 
M-100 - - - - - - + + + + + + 
 
 
3.2.7 Specificity of Fab antibodies MSC 1 – 12 
Many chemical compounds inhibiting CA IX function are known, while antibodies against CA IX 
used in clinics do not inhibit CA IX function. Nevertheless, those chemical drugs are unable to bind 
selectively to the CA IX isoform leading to a broad range inhibition of carbonic anhydrase 
isoforms and a lot of side-effects. Selectivity on the other hand is one of the advantages of 
antibodies. Antibodies are able to discriminate between very similar targets and thus to selectively 
bind one isozyme over another.  
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Figure  3.12: Selectivity of Fab antibodies MSC 1 – 12. Fab antibodies MSC 1 – 12 were tested in an ELISA on the 
most widely expressed isoform CA II which is present in the cytosol (black) and the two extracellular isoforms CA XII 
(grey) and CA XIV (white) showing high homology to CA IX. Binding was normalized to the staining cascade. P-values: 
*** < 0.001 compared to control Fab antibodies ESC 11 and ESC 14. 
 
In order to find antibodies combining these two features – selectivity and inhibition of CA IX 
function – the here selected antibodies were first tested in ELISA on different recombinant 
carbonic anhydrase isoforms to analyze, whether the here selected antibodies are indeed selectively 
binding CA IX (Figure  3.12). No binding to any of the other tested isoforms CA II, CA XII or 
CA XIV was observed. Coating of the plates with the corresponding carbonic anhydrase isoforms 
was confirmed with anti-His and for CA II in addition by using anti-CA II. 
 
3.2.8 Fab antibodies MSC 1 – 12 recognise a sterical epitope 
Fab antibodies MSC 1 – 12 were tested for their potential use in Western blot analysis on whole 
cell protein extracts from SKRC 17 MW1 cl4 cells as well as from SKRC 17 cells. None of the 
twelve tested Fab antibodies was able to recognise denatured CA IX protein (Figure  3.13) suggesting 
that they recognize a sterical epitope. In contrast, M75 did bind to two bands of 54 and 58 kDa 
corresponding to CA IX in whole cell protein extracts from SKRC 17 MW1 cl4 cells but not in 
those from SKRC 17 cells. 
 
 
 
 
 
 
 
Figure  3.13: Western blot using MSC 1 – 12 to stain CA IX. Fab antibodies MSC 1 – 12 were tested in a Western blot 
analysis on whole cell protein extracts of SKRC 17 MW1 cl4 (+) and SKRC 17 (-) cells (n = 3). Four representative Fab 
antibodies MSC 9 to MSC 12 are shown. CA IX expression was confirmed using M75 antibody. 
+       - +       - 
M75 
+       - +       - 
 
MSC 9 MSC 10 MSC 11 
CA IX 
+       - 
MSC 12 
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3.2.9 Affinity measurement of Fab antibodies on rhCA IX by surface plasmon 
resonance 
Affinity measurements were performed on a low-density rhCA IX-coated chip using surface 
plasmon resonance (Figure  3.14). All Fab antibodies showed significant binding to rhCA IX, with 
affinities ranging from 2 nM (MSC 11) to 66 nM (MSC 9) (Table  3.3).  
 
 
 
 
 
Figure  3.14: Affinity measurement of MSC 1 – 12 on rhCA IX. Affinity of Fab antibodies MSC 1 – 12 was tested 
using surface plasmon resonance on rhCA IX coated chips. 
 
MSC 1 
MSC 7 
MSC 6 MSC 5 MSC 4 
MSC 3 
MSC 8 
MSC 10 
MSC 9 
MSC 2 
MSC 12 MSC 11 
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Table  3.3: Affinities of Fab antibodies MSC 1 – 12 on rhCA IX. Affinity of the selected Fab antibodies for rhCA IX 
was analyzed by surface plasmon resonance. Association and dissociation rate constants (ka and kd, respectively) were 
locally fit to a 1:1 binding model, assuming bulk contribution and affinities (KD) were calculated. 
 ka [s-1] kd [s-1] KD [nM] 
MSC 1 0.919 0.00301 3 
MSC 2 0.732 0.00275 4 
MSC 3 1.340 0.02549 19 
MSC 4 0.394 0.01056 27 
MSC 5 2.315 0.04009 17 
MSC 6 0.846 0.03147 37 
MSC 7 0.510 0.00974 19 
MSC 8 0.856 0.01196 14 
MSC 9 1.478 0.09798 66 
MSC 10 0.468 0.00227 5 
MSC 11 1.854 0.00311 2 
MSC 12 1.822 0.01018 6 
 
3.2.10 Affinity measurement of Fab antibodies on rmCA IX by Biacore 
Affinity measurements were performed on a low-density rmCA IX-coated chip using surface 
plasmon resonance (Figure  3.15). Binding affinity to rmCA IX ranged from 4 nM to 163 nM and 
confirmed cross-reactivity of MSC 1, MSC 3, MSC 5, MSC 7, MSC 9 and MSC 12 to rmCA IX 
with MSC 3 being the best binder to the murine isoform (Table  3.4). For the other Fab antibodies 
affinities could not be determined due to too low binding to murine CA IX attended by too low 
response units. 
 
Table  3.4: Affinities of Fab antibodies MSC 1 – 12 on rmCA IX. Affinity of the selected Fab antibodies for rmCA IX 
was analyzed by surface plasmon resonance. Association and dissociation rate constants (ka and kd, respectively) were 
locally fit to a 1:1 binding model, assuming bulk contribution and affinities (KD) were calculated. Affinities of isoforms 
not listed in the table could not be determined due to too low binding to the murine isoform attended by too low response 
units 
 ka [s-1] kd [s-1] KD [nM] 
MSC 1 0.050 0.00174 35 
MSC 3 0.296 0.00125 4 
MSC 5 0.049 0.00225 46 
MSC 7 0.059 0.00196 34 
MSC 9 0.042 0.00170 41 
MSC 12 0.055 0.00273 50 
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Figure  3.15: Affinity measurement of MSC 1 – 12 on rmCA IX. Affinity of Fab antibodies MSC 1 – 12 was tested 
using surface plasmon resonance on rmCA IX coated chips. 
 
 
   
Figure  3.16: Production of pEE 12.4 MSC 11. (A) Specific binding of MSC 11 IgG to CA IX was confirmed in flow 
cytometry on SKRC 17 MW1 cl4. Grey: supernatants of one representative clone expressing MSC 11 IgG, white: 
staining cascade. (B) HC and LC of MSC 11 IgG were visualized in Western blot analysis and compared to a control 
huIgG. Purified supernatants from one representative clone are shown. 
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3.2.11 IgG production of selected antibodies 
Selected Fab antibodies were cloned into an IgG format using the LONZA GS system pEE 12.4. 
MSC 3 and MSC 11 were chosen for their high affinity to human CA IX with MSC 3 showing in 
addition cross-reactivity to murine CA IX. MSC 8 was chosen for inhibiting CA IX function by up 
to 57 % in a biochemical assay on membrane fragments (see  3.3 Inhibition of CA IX function using 
MSC 1 - 12). Correct cloning was confirmed by restriction digestion and subsequent sequencing. 
HEK 293 cells were transiently transfected with pEE 12.4 MSC 3, pEE 12.4 MSC 8 or pEE 12.4 
MSC 11 and supernatants were tested for IgG production in Western blot analysis. Specific binding 
was confirmed in flow cytometry. pEE 12.4 MSC 11 was stably transfected in NSO cells and 400 
clones were screened for IgG production in DotBlot and flow cytometry leading to the 
identification of 25 clones expressing MSC 11 IgG (Figure  3.16 A). HC and LC of IgGs were 
analyzed in Western blot analysis (Figure  3.16 B). For MSC 11 HC and LC a molecular weight of 50 
and 25 kDa respectively was determined. For large scale production of IgGs, pEE 12.4 MSC 3 and 
pEE 12.4 MSC 8 were stably transfected in CHO cells by the Ludwig Institute of cancer research in 
Melbourne, Australia and IgGs were subsequently purified. 
 
3.2.12 Tumour staining using MSC 3 IgG and MSC 11 IgG 
MSC 3 IgG and MSC 11 IgG were used to stain tumour sections of C51 tumours (Figure  3.17). 
MSC 3 showed specific staining of tumour tissue corresponding to staining of the perfusion marker 
pimonidazole. Staining for MSC 11 was negative corresponding to the fact, that this antibody 
recognizes only human CA IX but not murine CA IX. 
 
3.3 INHIBITION OF CA IX FUNCTION USING MSC 1 - 12 
Up to date, G250 is the only anti-CA IX antibody used in the clinic. This antibody is very potent in 
tumour-targeting (Oosterwijk, Bander et al. 1993; Divgi, Bander et al. 1998) but therapeutic 
efficiency is disputed (Divgi, Bander et al. 1998; Bleumer, Knuth et al. 2004; Brouwers, Mulders et 
al. 2005). G250 as well as the other anti-CA IX antibody M75 are both not described to inhibit 
CA IX function. Inhibition of CA IX function is thought to have a therapeutic effect, since 
acidification of tumour environment and neutralisation of intracellular pH both triggered by CA IX 
function are thought to provide a survival advantage to tumour cells. Chemical drugs on the other 
hand are able to inhibit CA IX function but are not specific and inhibit also other isoforms. 
Selective and inhibitory compounds would be of great interest for tumour therapy. Therefore, 
selected antibodies were tested for inhibition of CA IX function. 
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Figure  3.17: Immunofluorescence using MSC 3 IgG and MSC 11 IgG. Immunofluorescence of sections of C51 
tumours was performed using MSC 3 IgG or MSC 11 IgG (red) in combination with the perfusion marker pimonidazole 
(green). Nuclei were stained using DAPI (blue). 
 
3.3.1 Inhibition of CA IX function on membrane fragments using Fab antibodies 
A first screen for the CA IX inhibiting activity of the selected Fab antibodies was performed on 
membrane-fragments extracted from HCT 116 cells expressing CA IX. Carbonic anhydrase activity 
was determined using a biochemical assay that measures CO2 hydration by following the time-
course of medium acidification. Sample time courses of medium pH were obtained with 
membrane-fragments from HCT 116-CA IX or HCT 116-EV cells, and with membrane-free buffer 
(Figure  3.18 A). Carbonic anhydrase activity in HCT 116-EV membranes was bigger than 
spontaneous hydration rate in membrane-free buffer but considerably lower than in HCT 116-
CA IX membranes. Activity in HCT 116-EV membranes was in the same range as for HCT 116-
CA IX cells where total carbonic anhydrase activity was blocked using acetazolamide (HCT 116-
CA IX + ATZ), indicating that HCT 116-EV cells do not express significant surface carbonic 
anhydrase activity and that the carbonic anhydrase activity measured in HCT 116-CA IX 
membranes was primarily due to CA IX protein. The reaction constant was calculated and carbonic 
anhydrase activity was normalized to the values measured with buffer only (zero) and with control 
HCT 116-CA IX membranes (one) on the given day to compare data obtained on different days 
(Figure  3.18 B). The assay was repeated in the presence of 20 µg/ml Fab antibodies MSC 1 – 12, 
G250 IgG (Grabmaier, Vissers et al. 2000), anti-CA II IgG as a non-binding negative control and 
100 µM acetazolamide, a broad-spectrum small-molecule CA inhibitor (Figure  3.18). Five out of the 
tested Fab antibodies (namely MSC 2, MSC 5, MSC 8, MSC 10 and MSC 12) were able to block 
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CA IX activity significantly while the other tested Fab antibodies as well as G250 were not able to 
reduce CA IX activity. All five inhibitory Fab antibodies led to partial inhibition of CA IX activity, 
with MSC 8 having the greatest inhibitory effect. The potency of MSC 2, MSC 5, MSC 10 and 
MSC 12 Fab antibodies was much lower and, therefore, they were not investigated further. 
In order to see whether partial inhibition relies on too low Fab antibody concentrations, a dose 
response experiment was performed using higher concentrations of MSC 8 Fab (Figure  3.19). The 
dose response showed that concentrations of 20 g/ml used in the first experiment are already more 
than ten times more than saturation levels. Saturation levels are reached with concentrations of 1 –
 2 g/ml leading to a maximal inhibition of CA IX activity by up to 57 %. Half-maximal inhibition 
(IC50) was determined with concentrations around 0.33 µg/ml, which is equivalent to 6.5 nM for 
MSC 8 Fab antibody. 
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Figure  3.18: Inhibition of CA IX activity on membrane fragments using Fab antibodies. Fab antibodies MSC 1 – 12 
were tested for inhibitory potential on membrane fragments expressing CA IX at a concentration of 20 g/ml. (A) Time 
courses using membrane fragments of HCT 116-CA IX (continuous) or HCT 116-EV (dashed) are shown using only 
membrane fragments (black) or Fab antibody MSC 8 (blue). Spontaneous hydration rate was determined using buffer 
only (dotted). As control, total carbonic anhydrase activity was blocked with acetazolamide (red). (B) The reaction 
constant was calculated from the pH time-course and activity was normalized to HCT 116-EV (null) and HCT 116-
CA IX membrane fragments alone (one). Black: HCT 116-CA IX membrane fragments; grey: HCT 116-EV membrane 
fragments. 
(A) 
(B) 
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Figure  3.19: Dose response showing effect of MSC 8 Fab on CA IX activity. Concentrations of 0.1 g/ml to 
200 g/ml MSC 8 Fab were tested for inhibition of CA IX activity on membrane fragments expressing CA IX. Reaction 
constants were calculated from the pH time-courses, normalized to HCT 116-EV and HCT 116-CA IX membrane 
fragments and percentage of maximal inhibition (Imax) was determined. Concentration at half-maximal inhibition (dotted 
line, IC50) was calculated. 
 
 
 
3.3.2 Inhibition of CA IX function on membrane fragments using MSC 8 IgG 
Inhibition of CA IX function on membrane fragments of HCT 116 cells expressing CA IX or 
empty vector was repeated with MSC 3 IgG and MSC 8 IgG in order to see, if a bivalent IgG might 
be more potent in blocking CA IX activity than a monovalent Fab antibody (Figure  3.20). In 
agreement with previous experiments using Fab antibodies, inhibition of CA IX activity by MSC 8 
IgG could be confirmed, whereas MSC 3 IgG showed no inhibition. A dose response experiment 
revealed a maximal inhibition of CA IX activity by up to 76 % using MSC 8 IgG (Figure  3.21). 
Although inhibition with MSC 8 IgG was higher, half-maximal inhibition (IC50) was in the same 
range for both Fab antibody and IgG. An IC50 of 0.33 g/ml was determined corresponding to 
2.2 nM for MSC 8 IgG. 
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Figure  3.20: Inhibition of CA IX activity on membrane fragments using IgG. MSC 3 IgG and MSC 8 IgG were 
tested for inhibitory potential on membrane fragments expressing CA IX in order to confirm data obtained with Fab 
antibodies. (A) Time courses of CA IX activity with membrane fragments of HCT 116-CA IX (continuous) or HCT 116-
EV (dashed) are shown, using only membrane fragments (black), MSC 3 IgG (green) or MSC 8 IgG (blue). Spontaneous 
hydration rate was determined using buffer only (dotted). As control, total carbonic anhydrase activity was blocked with 
acetazolamide (red). (B) The reaction constant was calculated from the pH time-course and activity was normalized to 
HCT 116-EV (null) and HCT 116-CA IX membrane fragments alone (one). P-value: *** < 0.001. 
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Figure  3.21: Dose response showing effect of MSC 8 IgG on CA IX activity. Concentrations of 0.1 g/ml to 
100 g/ml MSC 8 IgG were tested for amount of inhibition on membrane fragments expressing CA IX. Reaction 
constants were calculated from the pH time-courses, normalized to HCT 116-EV and HCT 116-CA IX membrane 
fragments and percentage of maximal inhibition (Imax) was determined. Concentration at half-maximal inhibition (dotted 
line, IC50) was calculated. 
(A) 
(B) 
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Figure  3.22: Schematic representation of the NH3 flux across the membrane. NH4+ can not enter the cell in contrast 
to the non-ionized NH3. Influx of NH3 lowers pHS while efflux elevates it. This change in pH is reduced by conversion of 
protons and hydrogen carbonate (provided by the CO2/HCO3
- buffer used) to water and carbon dioxide. The reaction is 
enhanced by carbonic anhydrase activity. From (Swietach, Patiar et al. 2009). 
 
 
3.3.3 Measurement of CA IX activity on intact single cells 
Measurement of CA IX activity on membrane fragments is a simple way to screen antibodies for 
possible inhibition of CA IX function. Nevertheless, this method has several drawbacks like being 
performed under non-physiological conditions with respect to the ionic composition, alkaline pH 
and low temperature of experimental media. In addition, CA IX is extracted from its native cellular 
environment. To provide more physiological conditions, CA IX activity was measured in the native 
cellular environment on intact single HCT 116 cells. For this, surface extracellular pH (pHS) 
changes were determined after addition and subsequent removal of extracellular NH4+-containing 
solution driving a transmembrane NH3 flux (Figure  3.22). NH3 influx lowers pHS depositing 
extracellular H+-ions at the cell surface. Analogously, NH3 efflux raises pHS. 
pHS changes are reduced by the spontaneous reaction of H+-ions with HCO3-, namely from the 
physiological CO2/HCO3- buffer used. However, this reaction is strongly enhanced by extracellular 
carbonic anhydrase activity. The corresponding protocol and sample time-course measured in 
HCT 116-CA IX cells superfused with 5% CO2/12 mM HCO3 buffer is shown in Figure  3.23. 
Changing the superfusate buffer displaced pHs from the bulk extracellular pH of 7.2. These 
transient pHS changes after addition or removal of extracellular NH4+-containing solution were 
considerably larger when CA IX was inhibited with the commonly used broad-range carbonic 
anhydrase inhibitor acetazolamide, illustrating the importance of carbonic anhydrase activity in pH 
buffering by CO2/HCO3.  
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Figure  3.23: CA IX activity measurement on intact single cells. The experimental set-up is shown. The upper panel 
shows bulk extracellular pH and corresponding buffers. The lower panel shows addition and removal of ammonium 
chloride leading to transient pHS changes which are thereafter compensated by spontaneous reaction of protons and 
hydrogen carbonate and by catalysis of the same reaction by CA IX. Spontaneous reaction is simulated by addition of the 
broad range inhibitor acetazolamide. 
 
3.3.4 Inhibition of CA IX function on intact single cells 
Antibodies were tested on HCT 116 cells expressing CA IX (HCT 116-CA IX) or empty vector 
(HCT 116-EV). HCT 116-CA IX cells had much smaller transient pH changes than HCT 116-EV 
cells (Figure  3.24 A and B). In HCT 116-CA IX cells, acetazolamide led to a strong increase of 
transient pH changes, whereas almost no increase in HCT 116-EV cells was observed, indicating 
only marginal expression of other extracellular isoforms. If preincubated with HCT 116-CA IX, 
only MSC 8 IgG (Figure  3.24 C ii) but not MSC 8 Fab (Figure  3.24 C iii) was able to increase transient 
pH changes and thus inhibit CA IX function. However, continuous addition of MSC 8 Fab to 
superfusate restored inhibition of CA IX activity (Figure  3.24 C iv). In contrast, MSC 3 IgG was not 
able to inhibit CA IX function (Figure  3.24 C i). In HCT 116-CA IX cells, transient pH changes were 
42 % smaller than in ATZ treated control cells. MSC 8 IgG treated cells had transient pH changes 
only 16 % smaller than ATZ treated control. CA IX inhibition was calculated to be 48 % for 
MSC 8 Fab (when superfused continuously) and 61 % for MSC 8 IgG from the area under the 
curve (Figure  3.24 D). 
30 mM NH4Cl 
30 mM NH4Cl 
100 M acetazolamide 6.3 
6.9 
7.8 
7.2 
7.5 
6.6 
1 min 
su
rf
ac
e 
m
em
br
an
e 
pH
 
5 % CO2 / 12 mM HCO3- 10 mM Hepes/MES 
7.5 
6.9 
6.3 
bu
lk
 e
xt
ra
ce
llu
la
r p
H
 
7.2 
7.4 
6.4 
 3 Results 
70 
 
Figure  3.24: Influence of CA IX activity on pHS. Transient pHS changes were measured in (A) HCT 116-EV cells and 
(B) HCT 116-CA IX cells using only buffer (black) or inhibiting carbonic anhydrase activity with the broad range 
inhibitor acetazolamide (ATZ, grey). (C) Transient pHS changes were measured in HCT 116-CA IX cells using (i) 
MSC 3 IgG, (ii) MSC 8 IgG or MSC 8 Fab (iii) incubated with the cells or (iv) added to the superfusate. (D) Areas under 
the curve were calculated and normalized to the measurement made in the presence of acetazolamide. (i): incubated, (s): 
superfused. 
su
rf
ac
e 
pH
e 
7.3 
7.1 
6.9 
7.5 
su
rf
ac
e 
pH
e 
7.3 
7.1 
6.9 
7.5 
su
rf
ac
e 
pH
e 
7.3 
7.1 
6.9 
7.5 
su
rf
ac
e 
pH
e 
7.3 
7.1 
6.9 
7.5 
su
rf
ac
e 
pH
e 
7.3 
7.1 
6.9 
7.5 
su
rf
ac
e 
pH
e 
7.3 
7.1 
6.9 
7.5 
ar
ea
 u
nd
er
 p
H
e t
ra
ns
ie
nt
s 
(n
or
m
al
iz
ed
 to
 A
TZ
+ 
ca
rb
on
ic
 b
uf
fe
r) 
100 
80 
120 
60 
40 
20 
0 
Control  
CA activity 
Out-of-equilibrium pHe transients 
H
ep
es
 b
uf
fe
r 
co
nt
ro
l
M
S
C
 8
 Ig
G
 
M
S
C
 8
 F
ab
  (
i) 
M
S
C
 8
  F
ab
 (s
) 
M
S
C
 3
 Ig
G
 
H
C
T
11
6-
EV
HCT 116-CA IX
MSC 8 Fab (incubated) 
MSC 3 IgG 
MSC 8 Fab (superfused) 
MSC 8 IgG 
(A) HCT 116-EV 
(C) HCT 116-CA IX 
(B) HCT 116-CA IX
30 mM NH4Cl 30 mM NH4Cl 
i ii 
iii iv 
(D) 
 3.3 Inhibition of CA IX function using MSC 1 - 12 
71 
 
 
 
 
 
 
 
 
 
(A) SKRC 17 MW1 cl4 
(B) HeLa 
 3 Results 
72 
 
 
Figure  3.25: Internalization of CA IX. Internalization of CA IX was analyzed using Fab antibodies or IgGs on (A) 
SKRC 17 MW1 cl4 cells, (B) HeLa cells induced with 1 mM DMOG or (C) CT26 cells induced with 2 mM DMOG. For 
internalization MSC 3, MSC 8 or ESC 11 (red) were used, with the nuclei stained using DAPI (blue). White arrows in 
(A) indicate site of CA IX expression in one representative sample where at 4 °C expression is at the surface and at 37 °C 
in the cytosol. 
 
3.4 PHYSIOLOGICAL EFFECTS OF THE SELECTED ANTIBODIES 
3.4.1 Internalization of CA IX by MSC 3 IgG and MSC 8 IgG 
Both antibodies were then tested for their potential to trigger internalization of bound CA IX 
protein. MSC 3 IgG as well as MSC 8 IgG led to internalization of CA IX on stably transfected 
SKRC 17 MW1 cl4 cells (Figure  3.25 A) and HeLa cells chemically induced with 1 mM DMOG for 
48 h (Figure  3.25 B) when incubated at 37 °C for 2 h. If incubation was performed at 4 °C, the cell 
membrane was stained and no internalization was observed. In contrast, the corresponding Fab 
antibodies MSC 3 and MSC 8 did not induce internalization, regardless of the incubation 
temperature. On murine CT26 cells chemically induced with 2 mM DMOG no internalization was 
observed (Figure  3.25 C). MSC 3 Fab and IgG both stained the cell membrane and did not induce 
internalization. For the not cross-reactive antibody MSC 8 no signal could be detected on CT26. 
Control antibody ESC 11 did not led to any signal on the tested cell lines. 
(C) CT26 
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3.4.2 Influence of selected antibodies on cell proliferation 
Fab antibodies MSC 3, MSC 8 and MSC 11 as well as MSC 3 and MSC 8 IgG were tested for a 
possible anti-proliferative effect on different cell lines expressing CA IX constitutively or after 
hypoxic induction. When SKRC 52 cells were incubated for 3 days with 1 M MSC 3 or MSC 8 
Fab antibody cell number was not decreased compared to cell number when incubated with media 
without any additives (Figure  3.26). Cell number of SKRC 52 and HeLa cells induced in a hypoxic 
chamber at 0.2 % O2 decreased significantly when incubating the cells for 24 acetazolamide 
compared to incubation with medium without any additives. In contrast neither MSC 3 nor MSC 8 
IgG were able to do so at a concentration of 0.5 M, which is more than ten times higher than the 
concentration of MSC 8 IgG needed for maximal inhibition of CA IX activity. In addition, none of 
the tested Fab antibodies or IgGs was able to influence proliferation of any of the other tested cell 
lines SKRC 17, SKRC 17 MW1 cl4 or MCF-7 cells induced under hypoxia (data not shown).Under 
harsh conditions of low pH were cells have been proposed to depend on CA IX function to survive 
(Chiche, Ilc et al. 2009), survival of SKRC 17 MW1 cl4 was not augmented compared to SKRC 17 
cells (data not shown). Similarly, blocking by ATZ had no effect on cell survival, showing that 
survival under these conditions was indeed not CA IX dependent. 
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Figure  3.26: Proliferation assay. Survival of SKRC 52 cells and HeLa cells induced under hypoxia was analyzed using 
MSC 3 and MSC 8 Fab antibody (dark grey) or IgG (light grey) as well as acetazolamide (ATZ) and medium as control. 
Representative experiments analysed by crystal violet assay are shown. Samples were measured in triplicates. Results are 
shown as mean with standard deviation. Significance was calculated using a paired two-sided T-test. * : < 0.05. 
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3.5 COUPLING OF ANTIBODIES TO TOXIC MOIETIES 
Coupling to toxic moieties can be used to combine antibody specific targeting with functional 
effects of a toxic moiety. MSC 3 and MSC 11 were chosen for their high affinity on human CA IX 
with MSC 3 showing in addition cross-reactivity to murine CA IX. To increase a possible anti-
tumour effect, TNF was cloned into the pEE 12.4 vectors expressing the respective antibodies, 
creating an F(ab)2 fragment coupled to TNF. F(ab)2-TNF constructs were transiently expressed in 
HEK 293 cells and tested in Western blot (Figure  3.27 A) and in flow cytometry (Figure  3.27 B). All 
F(ab)2-TNF constructs as well as the control MSC 3 IgG could be detected by an anti-hu-Fab-POX 
antibody in immuno blotting and anti-hu-Fab-PE in flow cytometry, whereas anti-huTNF and anti-
muTNF stained only the F(ab)2-TNF constructs containing the corresponding TNF.  
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.27: Confirmation of TNF-constructs. Transient expression of F(ab)2-TNF constructs was validated in (A) 
Western blot analysis and (B) flow cytometry by staining with (i) anti-huFab-POX or anti-hu-Fab-PE, (ii) anti-huTNF 
and (iii) anti-muTNF. MSC 3 IgG served as a control. Flow cytometry: black: OptiMEM, blue: MSC 3 coupled to TNF 
green: MSC 11 coupled to TNF, solid line: huTNF, dotted line: muTNF. 
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Figure  3.28: TNF-assay. Functionality of the F(ab)2-TNF constructs was analyzed in a TNF-assay analyzing growth and 
survival of TNF sensitive Wehi S cells with variable doses of the F(ab)2-TNF constructs. One representative 
measurements using undiluted supernatant of transient transfections is shown. Proliferation was compared to the one with 
OptiMEM (supernatants from not transfected HEK 293 cells, negative control) and muTNF (positive control), both 
represented with dotted lines. P-values were calculated compared to samples with OptiMEM of the same dilution using a 
paired, two-sided T-test: *** < 0.001, ** < 0.01, * < 0.05. 
 
 
Functionality of the F(ab)2-TNF constructs was confirmed by killing of TNF sensitive Wehi S cells 
in a dose dependent manner (Figure  3.28). F(ab)2-TNF constructs were able to significantly inhibit 
survival of Wehi S cells when supernatant of HEK 293 cells transiently transfected with F(ab)2-
TNF constructs was added undiluted. Inhibition was in the same range as with recombinant 
muTNF. 
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4 DISCUSSION 
4.1 STRATEGIES TO SELECT NOVEL CA IX SPECIFIC ANTIBODIES  
This thesis describes the identification and characterization of twelve novel anti-CA IX antibodies 
MSC 1 – 12, among those five antibodies inhibiting CA IX enzymatic activity. There exist several 
strategies to identify novel antibodies. Immunization of mice led to the identification of many 
different anti-CA IX antibodies, among them M75 and G250 (Oosterwijk, Ruiter et al. 1986; 
Pastorekova, Zavadova et al. 1992; Zat'ovicova, Tarabkova et al. 2003). In this thesis, phage 
display using a semisynthetic human Fab antibody phage library consisting of 3.7·1010 different 
phages was chosen, which allows expressing selected Fab antibodies on the surface of phages or as 
soluble Fab antibodies (de Haard, van Neer et al. 1999). Phage display is much faster and more 
suited to select human antibodies than immunization of mice. Indeed, the murine antibody G250 
had to be humanized in order to avoid induction of human anti-mouse antibodies (Velders, 
Litvinov et al. 1994). In addition, antibodies with special features can be specifically enriched by 
phage display, e.g. selectivity for one special isoform or inhibition of CA IX enzymatic activity 
(reviewed in (Carter and Merchant 1997)). The PG-region of CA IX is very immunogenic due to 
the fact that human CA IX and murine CA IX differ mainly in this part, while the rest of the protein 
is much more conserved (Gut, Parkkila et al. 2002). Thus, most of the antibodies selected by 
immunization of mice recognize the PG domain, because this method does not allow selecting 
antibodies against self or closely related antigens. In contrast, inhibitory antibodies are most likely 
to bind to the catalytic CA domain. Selection of such inhibitory antibodies approved our choice to 
use phage display. 
Recently, two independent groups selected antibodies against CA IX by phage display. Xu and 
coworkers used a library consisting of 2.7·1010 different single chain antibodies (Xu, Lo et al. 
2010), which is in the same range as the library used here, while Ahlskog et al. used a smaller 
library consisting of 3·109 different single chain antibodies only (Silacci, Brack et al. 2005; 
Ahlskog, Schliemann et al. 2009). Using a large library increases the chance to identify new 
antibodies with the desired features. Indeed, five different antibodies inhibiting CA IX enzymatic 
activity were selected from our library and four from the library of Xu, while Ahlskog et al. were 
not able to identify an inhibitory antibody (Ahlskog, Schliemann et al. 2009; Xu, Lo et al. 2010).  
Selection by phage display on peptides allows selecting for antibodies specifically binding to the 
active pocket of the protein. Since at the beginning of this thesis no crystal structure of CA IX was 
available, models of CA IX structure based on CA II (Alterio, Vitale et al. 2006) were used to 
select peptides that include amino acids shown to be involved in CA II-sulfonamide interaction or 
in binding to the Zn2+ ion necessary for catalytic function. However, none of the Fab antibodies 
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selected against those peptides was able to bind to naturally expressed CA IX (data not shown), 
because the peptides chosen lie within the active pocket of CA IX and, although accessible to 
chemical compounds as sulfonamides, they might not be accessible to the much larger Fab 
antibodies. Therefore, selection was performed on recombinant CA IX protein leading to the 
selection of the twelve distinct anti-CA IX Fab antibodies MSC 1 – 12. The yield is comparable to 
the one of Xu et al. identifiying 14 distinct antibodies from their library (Xu, Lo et al. 2010). Seven 
of the here selected Fab antibodies were encountered several times, with two found even 16 times 
each (Figure  3.2 B). Another five groups selected contained only one clone. This enrichment of 
certain phages is typical for later rounds of selection, since with each round of selection phages 
binding to the selection antigen are enriched (reviewed in (Smith and Petrenko 1997)). The 
selection protocol used favours enrichment of phages binding with high affinity to rhCA IX, by 
using decreasing amounts of antigen in subsequent selection rounds and stringent washing leading 
to the loss of phages binding with low affinity to rhCA IX. High affinity binding as found for the 
here selected antibodies is favourable for later use in the clinic, since such antibodies stay longer at 
the site of action due to more stable antibody-antigen interactions. Nevertheless, too stringent 
conditions might lead to the loss of potential binders (reviewed in (Smith and Petrenko 1997)). 
Therefore, it is important to reduce the number of selection rounds to a minimum. The fact that 
some phages were enriched and others were encountered only once suggests that the number of 
selection rounds used was optimal. 
In this work, selection was performed on a recombinant protein composed of the whole 
extracellular part of CA IX. Xu et al. performed selection on CA IX containing paramagnetic 
proteoliposomes (Xu, Lo et al. 2010), while Ahlskog et al. used recombinant CA domain, to select 
for binders possibly inhibiting CA IX catalytic function (Ahlskog, Schliemann et al. 2009). 
Although the latter approach favours selection of antibodies binding to the catalytic domain, it 
showed to be more favourably to use the whole extracellular part of CA IX or even the whole 
protein, since those two approaches led to the identification of inhibitory antibodies. Using a 
recombinant protein consisting of the whole extracellular part reduces the amount of selected 
binder against the CA domain, but displays a more natural target. Although Ahlskog et al. could 
show that their recombinant protein is catalytically active (Ahlskog, Schliemann et al. 2009), the 
structure of the protein might be altered having an influence on binding of the selected antibodies 
to naturally expressed CA IX. 
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4.2 CHARACTERIZATION OF ANTI-CA IX ANTIBODIES 
The selected Fab antibodies MSC 1 – 12 bound specifically to recombinant human CA IX, to 
human CA IX expressed constitutively by stable transfection or by pVHL deficiency as well as to 
human CA IX expressed after chemical induction or under conditions of low oxygen levels. Every 
test system has its own strong points (Table  4.1). Therefore, it is necessary to combine those 
methods. In this work, binding of MSC 1 – 12 on CA IX expressed in those four test systems was 
identical indicating that those Fab antibodies are well suited for use in RCC as well as in hypoxic 
tumours. Thus, those four test systems were equivalent. Nevertheless, one Fab antibody, MSC 8, 
showed different binding to recombinant and naturally expressed protein. While in flow cytometry 
binding was in the same range as for all other antibodies, binding in ELISA on rhCA IX was much 
weaker, although still significant. This could point to an epitope presented differently in the 
recombinant protein than on cell lines. Such differences could arise from differences in 
glycosylation, slightly changed conformation in the recombinant protein or differences in 
multimerization. Problems with multimerization seem to be an issue for CA IX, where the 
extracellular part was shown to build dimers (Alterio, Hilvo et al. 2009) while the full length 
protein was proposed to form trimers (Pastorekova, Zavadova et al. 1992; Svastova, Hulikova et al. 
2004). In addition, coating of the recombinant protein to the plate might impair correct formation 
or accessibility of such an epitope. Since the KD value of 14 nM for MSC 8 Fab to rhCA IX lies 
within the range as for the other antibodies, binding differences seem to be due to the coating 
procedure. 
 
 
 
Table  4.1 Comparison of different test systems for CA IX expression. +/-: low levels of CA IX possible due to 
density mediated upregulation (Kaluz, Kaluzova et al. 2002). 
 stable transfection pVHL-deficiency chemical 
induction 
hypoxic induction 
constitutive expression yes yes no no 
negative cell line available yes no +/- +/- 
formation of active 
conformation 
no no no yes 
induction of other HIF-
regulated genes 
no yes yes yes 
cell lines artificial many RCC most cell lines most cell lines 
main field of use screening, antibody 
characterization 
model for RCC fast upregulation in 
many cell lines 
model for hypoxic 
tumours 
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Immunoprecipitation of the recombinant protein by M75 reduced the possibility to select antibodies 
recognizing an already known epitope, because the epitope of M75 was not accessible to phages. 
Nevertheless, it might be possible to select phages recognizing the same epitope since the linear 
epitope of M75 consists of a six fold tandem repeat of six aa in the PG region of CA IX with a 
minimal epitope provided by PGEEDLP (Zavada, Zavadova et al. 2000). None of the Fab 
antibodies MSC 1 – 12 was able to detect CA IX in Western blot analysis, indicating that they do 
not recognize linear epitopes (Figure  3.13). The epitope of G250 on the other hand is not yet known 
although there is evidence, that it is a sterical one (Chrastina, Zavada et al. 2003). Competition 
assays (Anna Zortea, unpublished data) revealed that binding of Fab antibodies MSC 1 – 12 to 
human CA IX was not competitive with M75 or G250. These data show that the here selected 
antibodies MSC 1 – 12 indeed are recognizing new epitopes not overlapping with the ones of the 
two established CA IX antibodies M75 or G250.  
None of the Fab antibodies showed a difference in binding under normoxic or hypoxic conditions 
(Figure  3.6). Therefore, epitopes within regions subject to conformational changes triggered by the 
absence of oxygen could be excluded. Not much is known about those conformational changes and, 
although the absence of oxygen per se seems to be needed (Dubois, Douma et al. 2007), also other 
factors might play a role. In addition, the time frame during which the hypoxic conformation is 
stable might be too short for detection of different binding behaviour of Fab antibodies on CA IX 
expressed under those two conditions. Dubois et al. suggested that the hypoxic conformation is lost 
after reoxygenation with a half life time of 30 min (Dubois, Douma et al. 2007). Nevertheless, 
fixation of cells after incubation with antibody under hypoxic conditions did not lead to any 
change, although loss of antibody binding due to conformational changes is avoided (Figure  3.7). 
This further supports the hypothesis that MSC 8 binds to a region that is not affected by 
conformational changes. Ongoing co-crystallization studies of MSC 8 with the extracellular part of 
CA IX will give more insights according to the epitope. 
 
Table  4.2 Comparison of antibodies and chemical compounds. 
 antibodies chemical compounds 
selectivity high low or absent 
inhibition of CA IX function up to 76 % (MSC 8 IgG) yes (many compounds) 
affinity high (2-66 nM) high-intermediate 
size intermediate (Fab antibodies) – large (IgG) small 
tissue penetration intermediate good 
blood clearance fast (Fab antibodies) – intermediate (IgG) mostly very fast 
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4.3 COMPARISON OF ANTIBODIES AND CHEMICAL COMPOUNDS 
To find the optimal therapeutic compound, factors as affinity and size of therapeutic compounds 
having an influence on tissue penetration and blood clearance as well as selectivity and inhibition 
of CA IX function have to be considered (Table  4.2). 
Affinities of the selected Fab antibodies against recombinant human CA IX are in the range of 2 –
 66 nM (Table  3.3), which is the usual range for monovalent Fab antibodies. The single chain 
antibodies described to inhibit CA IX function have similar affinities (1 – 100 nM) (Xu, Lo et al. 
2010), while the affinity of the most broadly used sulfonamide acetazolamide is 25 nM (Casey, 
Morgan et al. 2004). Other commonly used sulfonamides in the clinic show affinities in the same 
range, e.g. 27 nM for the antiglaucoma agent methazolamide (Casey, Morgan et al. 2004). The here 
selected antibodies therefore have up to tenfold higher affinity than those commonly used 
sulfonamides. Since antibodies are bivalent, their affinity is supposed to be even higher than for 
Fab fragments due to increased avidity. The here selected compounds are supposed to show slower 
blood clearance than commonly used sulfonamides, since high affinity leads to longer retention of 
therapeutic compounds at the site of interest (reviewed in (Tabrizi, Bornstein et al. 2010)). In 
contrast, it is expected that accessibility to tumour tissue is much higher for small chemical 
compounds like sulfonamides than for antibodies due to their much lower molecular weight. 
Similarly, Fab antibodies are expected to have much better tissue penetrasion than IgGs (reviewed 
in (Tabrizi, Bornstein et al. 2010)). Tissue penetration and blood clearance are important for 
duration of therapeutic effect. Long lasting effects reduce the number of injections necessary. If 
effects last too long on the other hand, side effects on tissue sites expressing CA IX under normal 
conditions and not only in cancer tissue, e.g. in the gastrointestinal tract, might cause some 
problems. Comparison of different formats therefore is very important to find the optimal form for 
administration and therapeutic efficiency.  
Selectivity for the CA IX isozyme is of great importance to guarantee targeted treatment and to 
avoid side effects as they are common using sulfonamides. This is especially important, since 
several carbonic anhydrase isoforms show high homology to CA IX (Opavsky, Pastorekova et al. 
1996). The probably most important carbonic anhydrase isoform is CA II, which is expressed in the 
cytosol. Due to its broad expression in many tissues (Pan, Leppilampi et al. 2006), its high catalytic 
activity and its involvement in respiration, pH homeostasis, bone development and function 
(reviewed in (Pastorekova, Parkkila et al. 2004; Supuran 2004)), selectivity compared to CA II is a 
major issue, although its intracellular expression prevents binding of the here selected Fab 
antibodies in the tissue. This restricted binding to extracellular epitopes is one major advantage of 
antibodies. Most sulfonamides in contrast can pass the membrane and, thus, bind also to 
intracellular isoforms. Although binding of antibodies to intracellular isoforms is not an issue, there 
exist three transmembrane or membrane-tethered carbonic anhydrase isoforms. Two of them with 
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high homology to CA IX (36 and 37 %, respectively), namely the cancer-related CA XII that is 
much less restricted to tumour tissue than CA IX (reviewed in (Pastorekova and Pastorek 2004)) 
and CA XIV were addressed. In contrast to many sulfonamides, none of the selected Fab antibodies 
bound to any of the tested isoforms confirming the high selectivity provided by antibodies. 
Chemical compounds on the other hand are very potent in inhibiting CA IX enzymatic activity. 
Many different sulfonamides inhibiting CA IX function are known, while neither G250 nor M75 
have been described to do so. In contrast, five of the Fab antibodies selected in this work reduced 
CA IX activity partially in a biochemical assay performed on membrane-fragments (Figure  3.18 B), 
with maximal inhibition of CA IX activity by up to 57 % using MSC 8 (Figure  3.19). Recently, an 
independent group has reported single chain antibodies selected by phage display with inhibitory 
effects on human CA IX (Xu, Lo et al. 2010). Inhibitory potential was tested on soluble CA IX 
fusion protein leading to reduction of CA IX activity by up to 50 %, which is in the same range as 
for the Fab antibodies selected in this work. In contrast, when using the corresponding IgG, 
inhibition using MSC 8 was augmented to 76 % (Figure  3.21), leading to the highest inhibition 
reported to date for antibodies. This increase in inhibition seems to rely on antibody format coupled 
to higher avidity. Half-maximal inhibition doses of 6.5 nM for Fab antibody and 2.2 nM for IgG 
can be explained by the same fact. Although selected against the CA domain of CA IX, none of the 
antibodies selected by Ahlskog et al. was able to inhibit CA IX function (Ahlskog, Schliemann et 
al. 2009). The single chain antibodies as well as the Fab antibodies selected here are therefore the 
first antibodies described to inhibit CA IX enzymatic activity.  
The inhibition assay of Xu et al. (Xu, Lo et al. 2010) was based on a similar approach as the assay 
used in this thesis, but inhibition on membrane fragments expressing CA IX used in this work 
might provide a more physiologically-accurate target for inhibition studies than inhibition of 
soluble fusion protein. Nevertheless, both assays are performed in a buffer system having a non-
physiological composition and an alkaline pH. This alkaline pH as well as low temperature of 
experimental media is necessary to bring the kinetics of the reaction within the resolving power of 
the pH electrode. In addition, CA IX is extracted from its native cellular environment, which might 
also have an influence on protein activity in the tumour tissue. Since CA IX might undergo 
structural changes during preparation of membrane fragments, the interaction with antibodies could 
be influenced. Additionally, possible interactions with other proteins could be important for proper 
CA IX function in intact cells. Disruption of such interactions might readily take place during 
preparation of membrane fragments. Since such interactions could either enhance or inhibit CA IX 
function, this inhibition assay might lead to false positive or false negative results, although it is the 
standard assay to screen antibodies for a possible inhibitory effect. Therefore, experiments were 
performed in the native cellular environment of intact single HCT 116 cells instead of membrane 
fragments.  
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Previous studies showed that CA IX does not have any influence on single cell pHi under 
physiological conditions (Swietach, Wigfield et al. 2008 9). However, CA IX is able to influence 
surface extracellular pH (pHS) (Swietach, Patiar et al. 2009). MSC 8 is the first antibody shown to 
inhibit CA IX function on intact single cells. Inhibition with MSC 8 Fab antibody could only be 
achieved by addition of MSC 8 Fab to the superfusate, while for MSC 8 IgG preincubation of cells 
was sufficient (Figure  3.24 D). In the single-cell approach, cells are constantly superfused with 
antibody free buffer. While the bivalent MSC 8 IgG associated persistently with CA IX protein and 
reduced CA IX activity although unbound antibody was washed away with superfusion, 
monovalent MSC 8 Fab antibody was washed away and no lasting inhibitory effect was produced.  
Spheroids can be used to simulate CA IX activity in tumour masses (Swietach, Vaughan-Jones et 
al. 2007; Swietach, Wigfield et al. 2008; Swietach, Patiar et al. 2009). MSC 8 Fab and MSC 8 IgG 
both were shown to have an effect on pH in spheroids (unpublished data), most likely due to 
inhibition of CA IX activity. The effect was only visible when spheroids were preincubated with 
antibodies indicating the time needed to penetrate into the spheroid core. This accessibility has to 
be taken into account for further experiments, since tumour tissue is often poorly vascularised and, 
therefore, accessibility might also be hampered.  
Taken together, an IgG is the format of choice for MSC 8 due to higher avidity, predicted slower 
blood clearance and much higher inhibition rate. Although penetration is diminished with 
increasing size of therapeutical compounds, the example of G250 shows that an IgG can 
specifically accumulate in hypoxic tumour tissue (Divgi, Pandit-Taskar et al. 2007). 
Although antibodies and chemical compounds both are able to inhibit CA IX catalytic activity, the 
mechanism of inhibition seems to differ. Carbonic anhydrase activity depends on Zn2+ in the active 
pocket. This Zn2+–ion binds a water molecule, thereby facilitating its interaction with the carbon 
dioxide and formation of hydrogen carbonate and a proton (reviewed in (Supuran 2004)). 
Sulfonamides inhibit CA IX function by binding to the Zn2+–ion, thereby preventing binding of a 
water molecule to the active pocket (Abbate, Casini et al. 2004; Weber, Casini et al. 2004; Di 
Fiore, De Simone et al. 2005; Menchise, De Simone et al. 2005; Alterio, Vitale et al. 2006; Di 
Fiore, Pedone et al. 2006). Fab antibodies on the other hand are too big to enter the active pocket 
and, therefore, have to inhibit CA IX function by other means. Beside binding to the active site and 
blocking the binding of the substrate, antibodies can impede binding of the substrate by sterical 
hindrance, trigger conformational changes of target proteins, or downregulate them by triggering 
internalization. 
Sterical hindrance by blocking the entry of the educts to the active site is very complicated to 
achieve for such small molecules like water and carbonic dioxide. That might be a reason, why the 
antibodies only partially inhibited CA IX (Figure  3.18 and Figure  3.20). Although single chain 
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antibodies, Fab antibodies and IgGs differ in their size with a Fab being approximately twice and 
an IgG six times as big as a single chain antibody, this difference might not reflect a difference in 
sterical hindrance, since the educts of CA IX are disappearing small compared to the different 
antibodies. Inhibition by the single chain antibodies selected by Xu and coworkers (Xu, Lo et al. 
2010) and inhibition by Fab antibodies selected in this work are indeed in the same range which 
might point towards a similar mechanism of inhibition. Nevertheless, it is doubtful whether sterical 
hindrance of such small educts could lead to inhibition by up to 76 % for MSC 8 IgG (Figure  3.21). 
Conformational changes due to antibody binding can impair binding of educts to CA IX or CA IX 
catalytic function itself. Furthermore, conformational changes of one CA IX molecule might 
change conformation of other CA IX molecules involved in the CA IX multimer leading to 
allosteric effects. Binding of antibodies to only one subunit could in addition be based on an 
epitope that is accessible just once in the multimer, possibly due to sterical hindrance by the 
antibodies themselves. In a dimeric complex as shown for the extracellular part of CA IX by 
crystallization (Alterio, Hilvo et al. 2009), only one binding site might be accessible for MSC 8. 
Nevertheless, this seems unlikely since the IgG led to higher inhibition than the Fab antibody 
although it is plausible that the three times bigger IgG will hamper binding to a second subunit 
much more than the Fab antibody. MSC 8 therefore is thought to inhibit CA IX function through 
conformational changes. Ongoing co-crystallization studies using MSC 8 and CA IX might give 
further insights in the exact mechanism of inhibition. 
The IC50 of MSC 8 Fab (0.33 g/ml, corresponding to 6.5 nM) is close to the KD value of 14 nM 
determined by surface plasmon resonance, suggesting that the epitope-binding step displays the 
event that inhibits CA IX catalytic activity. This is supported by the fact that on single cells 
addition of MSC 8 to the superfusate without prior incubation leads to inhibition of CA IX (Figure 
 3.24 C iv). Inhibition therefore is fast and does not rely on a general antibody-mediated effect, like 
IgG-induced internalization of CA IX. This is demonstrated by inhibition of CA IX function on 
singe cells by MSC 8 Fab although the Fab antibody is not able to trigger internalization due to 
missing cross-linking. In addition, inhibition could be observed in the biochemical assay on 
membrane fragments, where no internalization can take place. Nevertheless, beside direct 
inhibition of CA IX activity, indirect mechanisms can be important. It is plausible that, by 
decreasing the amounts of CA IX available on the cell surface, internalization reduces CA IX 
activity and, thus, might further increase the effect of CA IX inhibition by MSC 8 leading to an 
even more potent inhibitor. In contrast, none of the single chain antibodies selected by Xu and 
coworkers shown to inhibit CA IX function in the same range as the here selected antibodies was 
able to trigger internalization (Xu, Lo et al. 2010).  
Recently, an independent group selected an antibody triggering CA IX internalization on CA IX 
transfected cells and eliciting anti-cancer effects in mouse xenograft model of colorectal 
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carcinoma, although no CA IX inhibitory function was described (Zatovicova, Jelenska et al. 
2010). Therefore, by combining CA IX inhibitory potential and triggering of internalization not 
only on transfected, but also on chemically induced cells, MSC 8 might be even more potent. In 
addition, antibodies can directly trigger the immune response, e.g. by antibody mediated cellular 
cytotoxicity, and, thus, MSC 8 IgG not only inhibits CA IX function but also might lead to long 
lasting anti-tumour effects. 
 
4.4 POSSIBLE IMPLICATIONS OF THE SELECTED ANTIBODIES 
Inhibition of CA IX activity is thought to impede tumour growth. Nevertheless, MSC 8 was not 
able to inhibit growth of SKRC 52 cells and HeLa cells induced under hypoxic conditions (Figure 
 3.26). This is in line with reports that CA IX does not influence pHi in single cells under 
physiological conditions (Swietach, Wigfield et al. 2008) and that only under harsh conditions of 
low pH and in the absence of added extracellular hydrogen carbonate CA IX expression protects 
cells against cytoplasmic acidification, sustains ATP levels and promotes cell survival (Chiche, Ilc 
et al. 2009). In addition, CA IX function can be compensated by other extracellular carbonic 
anhydrases, e.g. CA XII (Chiche, Ilc et al. 2009). This report indicates that it might be necessary to 
use a mouse model providing the conditions found in tumour tissue to see an effect of inhibition of 
CA IX activity while in vitro no effect might be visible.  
Cross-reactivity of MSC 1 and MSC 3 is optimal for testing antibodies in a mouse model, since a 
syngeneic mouse model can be used and possible side effects due to binding to CA IX expressed in 
normal tissue are easily detectable. Affinities of the selected Fab antibodies against recombinant 
murine CA IX were in the range of 4 – 50 nM (Table  3.3), which is in the same range as on human 
CA IX. A similar range of affinities is ideal to transfer therapy in a mouse models to humans. 
MSC 3 was able to specifically stain C51 tumour sections and staining using MSC 3 corresponded 
to a staining using the hypoxia marker pimonidazole. Overlapping signals of CA IX expression and 
pimonidazole have been reported in some cases, while in other tumour sections no correlation 
could be observed (Troost, Bussink et al. 2005; Ahlskog, Schliemann et al. 2009) and, therefore, is 
thought to be tumour specific. Nevertheless, the here selected antibody MSC 3 is very useful for 
staining of CA IX in tumour sections and, thus, has possible applications in biodistribution. 
Another application of antibodies is the delivery of therapeutic moieties to target cells expressing 
an antigen of interest. One possibility for such a toxic moiety is TNF. Previous studies by Bauer et 
al. demonstrated specific accumulation and retention of a cG250-TNF construct at tumour sites in 
xenografted mice resulting in growth inhibition and improved progression free survival (Bauer, 
Oosterwijk-Wakka et al. 2009). In this work, F(ab)2-TNF constructs were produced containing an 
F(ab)2 part specifically binding to tumour-associated CA IX and a TNF part which kills TNF-
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sensitive cells by a receptor mediated mechanism. TNF activity was confirmed by killing TNF 
sensitive Wehi S cells in a dose dependent manner (Figure  3.28). To further address specific 
accumulation of the constructs in tumour tissue mice experiments are needed.  
Antibodies can not only be used to deliver therapeutic moieties to target cells. Internalization 
triggered by antibodies can be utilised to deliver radioactive moieties or cytotoxic compounds 
coupled to antibodies directly into the target cells. Once inside the cell, such compounds can 
accumulate and fulfil their respective function. MSC 3 IgG and MSC 8 IgG triggering 
internalization of CA IX are therefore promising tools for radioactive labelling or specific killing of 
CA IX positive cells. 
In conclusion, the here selected antibodies are promising tools for tumour targeting and tumour 
therapy. They combine high specificity and inhibition of CA IX function. In addition they trigger 
internalization of CA IX which further reduces CA IX levels at the cell surface. Therefore, they 
might lead to enhanced therapy of solid tumours and extend beyond the use of already known 
antibodies or chemical compounds. 
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5 APPENDIX 
5.1 SEQUENCES 
5.1.1 CA IX DNA sequence  
(EMBL Data Library, X66839) 
gcccgtacac accgtgtgct gggacacccc acagtcagcc gcatggctcc cctgtgcccc 60 
agcccctggc tccctctgtt gatcccggcc cctgctccag gcctcactgt gcaactgctg 120 
ctgtcactgc tgcttctgat gcctgtccat ccccagaggt tgccccggat gcaggaggat 180 
tcccccttgg gaggaggctc ttctggggaa gatgacccac tgggcgagga ggatctgccc 240 
agtgaagagg attcacccag agaggaggat ccacccggag aggaggatct acctggagag 300 
gaggatctac ctggagagga ggatctacct gaagttaagc ctaaatcaga agaagagggc 360 
tccctgaagt tagaggatct acctactgtt gaggctcctg gagatcctca agaaccccag 420 
aataatgccc acagggacaa agaaggggat gaccagagtc attggcgcta tggaggcgac 480 
ccgccctggc cccgggtgtc cccagcctgc gcgggccgct tccagtcccc ggtggatatc 540 
cgcccccagc tcgccgcctt ctgcccggcc ctgcgccccc tggaactcct gggcttccag 600 
ctcccgccgc tcccagaact gcgcctgcgc aacaatggcc acagtgtgca actgaccctg 660 
cctcctgggc tagagatggc tctgggtccc gggcgggagt accgggctct gcagctgcat 720 
ctgcactggg gggctgcagg tcgtccgggc tcggagcaca ctgtggaagg ccaccgtttc 780 
cctgccgaga tccacgtggt tcacctcagc accgcctttg ccagagttga cgaggccttg 840 
gggcgcccgg gaggcctggc cgtgttggcc gcctttctgg aggagggccc ggaagaaaac 900 
agtgcctatg agcagttgct gtctcgcttg gaagaaatcg ctgaggaagg ctcagagact 960 
caggtcccag gactggacat atctgcactc ctgccctctg acttcagccg ctacttccaa 1020 
tatgaggggt ctctgactac accgccctgt gcccagggtg tcatctggac tgtgtttaac 1080 
cagacagtga tgctgagtgc taagcagctc cacaccctct ctgacaccct gtggggacct 1140 
ggtgactctc ggctacagct gaacttccga gcgacgcagc ctttgaatgg gcgagtgatt 1200 
gaggcctcct tccctgctgg agtggacagc agtcctcggg ctgctgagcc agtccagctg 1260 
aattcctgcc tggctgctgg tgacatccta gccctggttt ttggcctcct ttttgctgtc 1320 
accagcgtcg cgttccttgt gcagatgaga aggcagcaca gaaggggaac caaagggggt 1380 
gtgagctacc gcccagcaga ggtagccgag actggagcct agaggctgga tcttggagaa 1440 
tgtgagaagc cagccagagg catctgaggg ggagccggta actgtcctgt cctgctcatt 1500 
atgccacttc cttttaactg ccaagaaatt ttttaaaata aatatttata at 1552 
 
 5 Appendix 
88 
5.1.2 CA IX amino acid sequence 
(NCBI, Q16790.2 GI:83300925) 
MAPLCPSPWL PLLIPAPAPG LTVQLLLSLL LLVPVHPQRL PRMQEDSPLG GGSSGEDDPL 60 
GEEDLPSEED SPREEDPPGE EDLPGEEDLP GEEDLPEVKP KSEEEGSLKL EDLPTVEAPG 120 
DPQEPQNNAH RDKEGDDQSH WRYGGDPPWP RVSPACAGRF QSPVDIRPQL AAFCPALRPL 180 
ELLGFQLPPL PELRLRNNGH SVQLTLPPGL EMALGPGREY RALQLHLHWG AAGRPGSEHT 240 
VEGHRFPAEI HVVHLSTAFA RVDEALGRPG GLAVLAAFLE EGPEENSAYE QLLSRLEEIA 300 
EEGSETQVPG LDISALLPSD FSRYFQYEGS LTTPPCAQGV IWTVFNQTVM LSAKQLHTLS 360 
DTLWGPGDSR LQLNFRATQP LNGRVIEASF PAGVDSSPRA AEPVQLNSCL AAGDILALVF 420 
GLLFAVTSVA FLVQMRRQHR RGTKGGVSYR PAEVAETGA   459 
 
5.1.3 huTNF 
GGTACCCACACCGTGGCCGGCCTCTGCGCCTGGGCCCAGCTCTGTCCCACACCGCGGTCACATGGCACCTTTTCTCTTCCA
GCCTCCACCAAGGGCCCAAGCGTCTTTCCTCTGGCCCCCAGCAGCAAGTCTACCAGCGGCGGCACTGCCGCTCTGGGCTGT
CTGGTGAAGGACTACTTCCCCGAGCCCGTGACCGTCAGCTGGAACTCTGGCGCTCTGACCTCCGGCGTGCACACCTTCCCC
GCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTAC
ATCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGCGACAAGACCCACACC
TGCCCCCCTTGCCCTGGCGGCGGAGGAAGCAGCAGCTCCAGGACCCCCAGCGACAAGCCCGTGGCCCATGTGGTGGCCAAC
CCCCAGGCCGAGGGCCAGCTGCAGTGGCTGAACAGAAGGGCCAACGCCCTGCTGGCCAACGGCGTGGAGCTGAGGGACAAC
CAGCTGGTCGTGCCAAGCGAGGGCCTCTACCTGATCTACAGCCAGGTGCTGTTCAAGGGCCAGGGCTGCCCCAGCACCCAC
GTGCTGCTGACCCACACCATCAGCAGGATCGCCGTGAGCTACCAGACCAAGGTGAACCTGCTGTCCGCCATCAAGAGCCCC
TGCCAGAGAGAGACCCCCGAGGGCGCCGAGGCCAAGCCTTGGTACGAGCCCATCTACCTGGGCGGCGTGTTCCAGCTCGAA
AAGGGCGACAGACTGAGCGCCGAGATCAACAGGCCCGACTACCTGGACTTCGCCGAGAGCGGCCAGGTGTACTTCGGCATC
ATCGCCCTGTGACTCGAGCTC 
GGCCGGCC FseI, CTCGAG XhoI 
 
5.1.4 muTNF 
GGTACCCACACCGTGGCCGGCCTCTGCGCCTGGGCCCAGCTCTGTCCCACACCGCGGTCACATGGCACCTTTTCTCTTCCA
GCCTCCACCAAGGGCCCAAGCGTGTTCCCTCTGGCCCCCAGCAGCAAGAGCACCTCTGGCGGCACAGCTGCTCTGGGCTGC
CTGGTGAAGGACTACTTCCCCGAGCCTGTGACTGTGAGCTGGAACAGCGGCGCTCTGACCTCCGGCGTGCACACTTTCCCT
GCCGTCCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTAC
ATCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGCGACAAGACCCACACC
TGCCCCCCTTGCCCTGGCGGCGGAGGAAGCGACGAGCCTGTCGCCCATGTGGTGGCCAACCATCAGGTGGAGGAACAGCTG
GAATGGCTGTCCCAGAGGGCCAACGCCCTGCTGGCCAACGGCATGGACCTGAAGGACAACCAGCTGGTCGTGCCCGCCGAC
GGCCTGTATCTGGTGTACTCTCAGGTGCTGTTCAAGGGCCAGGGCTGCCCCGACTACGTGCTGCTGACCCATACAGTGAGC
AGGTTCGCCATCAGCTACCAGGAAAAGGTCAACCTGCTGTCCGCCGTGAAGAGCCCCTGCCCCAAGGACACCCCCGAGGGC
GCCGAGCTGAAGCCTTGGTACGAGCCCATCTACCTGGGCGGCGTGTTCCAGCTCGAAAAGGGCGACCAGCTGTCTGCCGAG
GTGAACCTGCCCAAGTACCTGGACTTCGCCGAGAGCGGCCAGGTGTACTTCGGCGTGATCGCCCTGTGACTCGAGCTC 
GGCCGGCC FseI, CTCGAG XhoI 
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5.2 ABBREVIATIONS 
5.2.1 Commonly used abbreviations 
A adenine 
aa amino acid 
ADCC antibody dependent cellular cytotoxicity 
AE anionic exchanger 
Amp ampicillin 
APS ammonium persulfate 
ATP adenosintriphosphat 
ATZ acetazolamide 
bp base pair 
BSA bovine serum albumin 
C cytosine 
CA carbonic anhydrase 
CA domain carbonic anhydrase domain, catalytically active domain 
CA IX  carbonic anhydrase IX 
CDR complementarity determining region 
DAPI 4’,6-Diamidino-2-phenylindole 
dH2O deionised water 
DMEM  Dulbecco’s modified eagle medium 
DMOG dimethyloxaloylglycin 
DMSO dimethyl sulfoxide 
DNA  desoxyribonucleic acid 
dNTP deoxyribonucleotide 
DTT dithiothreitol; IUPAC: (2S,3S)-1,4-Bis-sulfanylbutane-2,3-diol 
E. coli  Escherichia coli 
EDTA ethylenediaminetetraacetic acid 
ELISA enzyme linked immuno sorbant assay 
EtBr ethidium bromide; IUPAC: 3,8-Diamino-5-ethyl-6-phenylphenanthridinium bromide 
EtOH ethanol 
Fab fragment, antigen binding 
FAP fibroblast activation protein 
FBS fetal bovine serum 
Fc fragment, crystallisable 
FITC Fluorescein isothiocyanate 
G guanine 
GMFI geometric mean fluorescence intensity 
HC heavy chain 
HEK human embryonic kidney 
Hepes 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIF hypoxia inducible factor 
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HIF-1 hypoxia inducible factor 1 
HLH helix-loop-helix 
HRP horseradish peroxidase 
hu human 
IC domain intracellular domain of CA IX 
IFN interferon 
Ig immunoglobulin 
IgG  immunoglobulin G 
IL interleukin 
IPTG  isopropyl--thiogalaktopyranoside 
Kan kanamycin 
kb kilo base pair 
KCl potassium chloride 
kDa kilo dalton 
K-gluconate potassium gluconate 
LB Luria-Bertani broth 
LC light chain 
MCF-7 Michigan Cancer Foundation - 7 
MDCK Madin Darby canine kidney 
MES 2-(N-morpholino)ethanesulfonic acid 
mRNA messenger ribonucleic acid 
MSX L-methionine sulphoximine 
mu  murine 
NCBI National Center for Biotechnology Information 
NGS normal goat serum 
nt nucleotide 
o/n over night 
OD optical density at 
ORF open reading frame 
PCR polymerase chain reaction 
PE R-phycoerythrin 
PEG polyethylene glycol 6000 
PFA paraformaldehyde 
pfu plaque forming unit 
PG domain proteoglycan-like attachment domain of CA IX 
pHe extracellular pH 
pHi intracellular pH 
pHs surface pH 
PI3K phosphatidylinositol 3-kinase 
pVHL von Hippel-Lindau protein 
rhCA II recombinant human carbonic anhydrase II 
rhCA IX recombinant human carbonic anhydrase IX 
rhCA XII recombinant human carbonic anhydrase XII 
rhCA XIV recombinant human carbonic anhydrase XIV 
rmCA IX recombinant mouse carbonic anhydrase IX 
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RNA ribonucleic acid 
RPMI  Roswell Park Memorial Institute (cell culture medium) 
RU response units 
SDS sodium dodecylsulfate 
SDS-PAGE sodiumdodecylsulfate polyacrylamid gel electrophoresis 
T thymine 
TAE tris-acetate-EDTA buffer 
TEMED tetramethylethylenediamine 
Tet tetracycline 
TM domain transmembrane domain of CA IX 
TNF tumour necrosis factor 
Tris tris(hydroxymethyl)aminomethane 
TY yeast tryptone 
UV ultraviolet 
VHL von Hippel-Lindau 
-OG octyl β-D-glucopyranoside 
 
 
5.2.2 Commonly used units 
% percent 
% v/v percent volume per volume 
% w/v percent weight per volume 
°C degree Celsius 
d day 
g gram 
h hour 
l litre 
M molar 
mg milliogram 
ml millilitre 
mM millimolar 
mol mole 
nM nanomolar 
rpm revolutions per minute 
s second 
u unit 
g microgram 
l microlitre 
M micromolar 
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5.2.3 Chemical formula 
CaCl2 calcium chloride 
CoCl2 cobalt chloride / cobalt(II) chloride 
H2SO4 sulphuric acid 
HCl hydrochloric acid 
KCl potassium chloride 
KH2PO4 potassium dihydrogen phosphate 
MgCl2 magnesium chloride 
Na2HPO4 disodium hydrogen phosphate 
NaCl sodium chloride 
NaHCO3 sodium bicarbonate; IUPAC: sodium hydrogen carbonate 
NaOH sodium hydroxide 
NH4Cl ammonium chloride 
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